UK Dementias Platform
Lead Research Organisation:
University of Oxford
Department Name: Psychiatry
Abstract
The UK Dementias Platform (UKDP) is a radically new approach to dementias research, bringing together data from around 2,000,000 study participants from 22 cohorts to try and discover the causes of dementia and to find out ways of slowing it down. The platform has been funded to the level of £4.5M and invited to apply for a further £7.5M.
To achieve our goals of discovering the causes of dementia and finding out ways to slow it down, we will analyse data collected over many decades from throughout the UK to identify targets for drugs studies.
We will also enrich strategically selected cohorts to provide resources for dementias research in general. This will involve finding out how the early dementia processes begin, how our genes affect our risk of dementia and where our body goes wrong in maintaining and repairing itself.
There are many practical challenges involved in doing this work including knowing how to assess dementia in large studies where having everyone examined by a doctor would be prohibitively expensive. Another challenge is how to measure cognitive decline in the population as when people begin to decline they are frequently less motivated to do cognitive tests.
There are also important ethical issues surrounding this work and we have specific projects looking at ethical legal and social issues surrounding taking part in detailed measurement studies as well as in considering brain donation.
To help make an impact as soon as possible, we will work closely with industry partners who are best placed to turn basic scientific knowledge into effective therapies.
Even if we cannot cure dementia in the short term, it would count as a success if we found ways of slowing it down so that nobody need lose their dignity as they grew older.
To achieve our goals of discovering the causes of dementia and finding out ways to slow it down, we will analyse data collected over many decades from throughout the UK to identify targets for drugs studies.
We will also enrich strategically selected cohorts to provide resources for dementias research in general. This will involve finding out how the early dementia processes begin, how our genes affect our risk of dementia and where our body goes wrong in maintaining and repairing itself.
There are many practical challenges involved in doing this work including knowing how to assess dementia in large studies where having everyone examined by a doctor would be prohibitively expensive. Another challenge is how to measure cognitive decline in the population as when people begin to decline they are frequently less motivated to do cognitive tests.
There are also important ethical issues surrounding this work and we have specific projects looking at ethical legal and social issues surrounding taking part in detailed measurement studies as well as in considering brain donation.
To help make an impact as soon as possible, we will work closely with industry partners who are best placed to turn basic scientific knowledge into effective therapies.
Even if we cannot cure dementia in the short term, it would count as a success if we found ways of slowing it down so that nobody need lose their dignity as they grew older.
Technical Summary
The UK Dementias Platform (UKDP) is a radically new approach to dementias research, providing a highly efficient and cost-effective translation pipeline from basic discovery through to early phase trials (Fig 1). By combining the analytic and statistical power of >20 clinical and population cohorts representing 2M participants and creating a large readiness cohort, UKDP will create an optimal environment for basic discovery activities relevant to the clinical progression and human impact of dementia. Although UKDP is intended as a strategic and sustainable resource generating increasing scientific benefit over time, it will also deliver short and medium term benefits through the analysis of existing data, the enrichment of strategically selected cohorts, developing new ways of working with industry, and generating interest and further funding for dementias research generally.
A single portal informatics hub (funded in stage 1) will be used for integrating data from participating cohorts and triangulating evidence between cohorts. The stage 2 proposal focuses on providing strategic resources for EM by enriching strategically selected cohorts, addressing key methodological issues and pump-priming a programme of EM studies.
Further development of the platform is anticipated as the opportunities it provides are more widely understood. For example, predicated on the ability of the platform's ability to provide accurately risk stratification, MRC and NIHR have recently funded a deep and frequent Phenotyping (DFP) feasibility study with a view to providing a further £5M for the full study. The DFP project may be considered a stage 3 development of UKDP and is an example of how UKDP can be used to leverage further resource for dementias research.
A single portal informatics hub (funded in stage 1) will be used for integrating data from participating cohorts and triangulating evidence between cohorts. The stage 2 proposal focuses on providing strategic resources for EM by enriching strategically selected cohorts, addressing key methodological issues and pump-priming a programme of EM studies.
Further development of the platform is anticipated as the opportunities it provides are more widely understood. For example, predicated on the ability of the platform's ability to provide accurately risk stratification, MRC and NIHR have recently funded a deep and frequent Phenotyping (DFP) feasibility study with a view to providing a further £5M for the full study. The DFP project may be considered a stage 3 development of UKDP and is an example of how UKDP can be used to leverage further resource for dementias research.
Planned Impact
The platform will use several vehicles to deliver impact.
These were described in stage 1.
In summary:
For the academic community, in addition to the proposals mad in stage 1, we will develop a network of partnerships and operate a system of working groups to actively consult the UK academic community and world experts on the direction, technologies and collaborations of the platform. Our aim is to 1) base the science of the platform on the best information available, 2) create momentum in dementias research by being inclusive of, and synergistic with, other initiatives.
For industry, partnership discussions are already underway with exchanges of ides, interests and needs between academic and industry stakeholders. Industry have identified their need for access to conversion (early MVI to dementia cohorts and for experimental medicine studies to conform to regulatory requirements.
We remain committed to raising the profile of contemporary debate about dementia and its treatment. We wish to encourage a culture of commitment to solving this problem. By increasing awareness at all levels of society we intend to leverage resources for the platform and for dementia research in general, to increase awareness of the need for earlier interventions and better targeted treatment in general by health service providers and the public alike.
Engagement with the general public and with patients and carers is a very important part of our mission. This serves not only to communicate our research findings and their relevance but also to address such issues as stigma in society and the research culture in the NHS in relation to dementia and older people. In addition to using the platform web-site to communicate to the general public, we will also liaise with charities and advocate groups such as Age UK and the Alzheimer's Society to promote our work and findings and to engage them in shaping the work programme.
In addition we will have a dedicated free-phone number available 6 days a week and a communications officer at 50% FTE over 5 years whose responsibility is to develop and implement a communications and public engagement strategy.
These were described in stage 1.
In summary:
For the academic community, in addition to the proposals mad in stage 1, we will develop a network of partnerships and operate a system of working groups to actively consult the UK academic community and world experts on the direction, technologies and collaborations of the platform. Our aim is to 1) base the science of the platform on the best information available, 2) create momentum in dementias research by being inclusive of, and synergistic with, other initiatives.
For industry, partnership discussions are already underway with exchanges of ides, interests and needs between academic and industry stakeholders. Industry have identified their need for access to conversion (early MVI to dementia cohorts and for experimental medicine studies to conform to regulatory requirements.
We remain committed to raising the profile of contemporary debate about dementia and its treatment. We wish to encourage a culture of commitment to solving this problem. By increasing awareness at all levels of society we intend to leverage resources for the platform and for dementia research in general, to increase awareness of the need for earlier interventions and better targeted treatment in general by health service providers and the public alike.
Engagement with the general public and with patients and carers is a very important part of our mission. This serves not only to communicate our research findings and their relevance but also to address such issues as stigma in society and the research culture in the NHS in relation to dementia and older people. In addition to using the platform web-site to communicate to the general public, we will also liaise with charities and advocate groups such as Age UK and the Alzheimer's Society to promote our work and findings and to engage them in shaping the work programme.
In addition we will have a dedicated free-phone number available 6 days a week and a communications officer at 50% FTE over 5 years whose responsibility is to develop and implement a communications and public engagement strategy.
Organisations
- University of Oxford (Lead Research Organisation)
- ETH Zurich (Collaboration)
- Progressive Supranuclear Palsy Association (PSPA) (Collaboration)
- Catalan Health Institute (ICS) (Collaboration)
- University of California, San Francisco (Collaboration)
- University of Liege (Collaboration)
- National Institute on Aging (Collaboration)
- OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- Janssen Biotech, Inc. (Collaboration)
- EMBL European Bioinformatics Institute (EMBL - EBI) (Collaboration)
- University of San Francisco (Collaboration)
- The Hong Kong University of Science and Technology (Collaboration)
- Stanford University (Collaboration)
- Ludwig Maximilian University of Munich (LMU Munich) (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- European Medical Information Framework (EMIF) (Collaboration)
- Life Molecular Imaging (Collaboration)
- HARVARD UNIVERSITY (Collaboration)
- University of Luxembourg (Collaboration)
- Wellcome Trust (Collaboration)
- Newcastle University (Collaboration)
- Alzheimer's Research UK (Collaboration)
- German Centre for Neurodegenerative Diseases (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- University of East Anglia (Collaboration)
- UNIVERSITY OF EXETER (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Observational Health Data Sciences and Informatics (Collaboration)
- Alan Turing Institute (Collaboration)
- SomaLogic (Collaboration)
- Janssen Research & Development (Collaboration)
- University of California, Irvine (Collaboration)
- Eli Lilly & Company Ltd (Collaboration)
- Johnson & Johnson (Collaboration)
- University of Lille (Collaboration)
- Apellis Pharmaceutical (Collaboration)
- SWANSEA UNIVERSITY (Collaboration)
- National Institutes of Health (NIH) (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
- University of Glasgow (Collaboration)
- MRC Dementias Platform UK (Collaboration)
- University of Oslo (Collaboration)
- The International Parkinson Disease Genomics Consortium (Collaboration)
- University of Southern Denmark (Collaboration)
- Eisai Ltd (Collaboration)
- JPND Research (Collaboration)
- University of Bologna (Collaboration)
- AstraZeneca (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- University of Southern California (Collaboration)
- Cardiff University (Collaboration)
- Bristol-Myers Squibb (Collaboration)
- IRCCS Policlinico San Donato (Collaboration)
- Amyloid Imaging to Prevent Alzheimer's Disease (Collaboration)
- Government of Wales (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- UNIVERSITY OF LIVERPOOL (Collaboration)
- University of Barcelona (Collaboration)
- University of Bristol (Collaboration)
- University of Milan (Collaboration)
- Araclon Biotech (Collaboration)
- University College London (Collaboration)
- University of Manchester (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- McGill University (Collaboration)
- University of Gothenburg (Collaboration)
- Washington University in St. Louis (Collaboration)
- UK Dementia Research Institute (Collaboration)
- WAVE Life Sciences (Collaboration)
- Syracuse University (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- Polytechnic University of Milan (Collaboration)
- Alzheimer's Disease Neuroimaging Initiative (Collaboration)
- Ixico (Collaboration)
- University of Göttingen (Collaboration)
- University of Leuven (Collaboration)
- EU Joint Programme - Neurodegenerative Disease Research (JPND) (Collaboration)
Publications
Agarwal D
(2020)
A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders.
in Nature communications
Ahmad S
(2018)
Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study.
in Alzheimer's & dementia : the journal of the Alzheimer's Association
Akbari A
(2020)
Creating A Research Ready Data Asset and Empowering Dynamic and Efficient Research: The Sail Dementia E-Cohort (SDEC)
in International Journal of Population Data Science
Akingbuwa WA
(2020)
Genetic Associations Between Childhood Psychopathology and Adult Depression and Associated Traits in 42 998 Individuals: A Meta-analysis.
in JAMA psychiatry
Alber J
(2019)
White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities.
in Alzheimer's & dementia (New York, N. Y.)
Alex B
(2019)
Text mining brain imaging reports
in Journal of Biomedical Semantics
Allan CL
(2016)
Sub-threshold depressive symptoms and brain structure: A magnetic resonance imaging study within the Whitehall II cohort.
in Journal of affective disorders
Allardyce J
(2018)
Association Between Schizophrenia-Related Polygenic Liability and the Occurrence and Level of Mood-Incongruent Psychotic Symptoms in Bipolar Disorder.
in JAMA psychiatry
Title | 3 video interviews with research participant, senior industry scientist and senior academic researcher |
Description | Three video interviews to bring the importance of dementia research and the DPUK project to life for our general public audience through our social media channels (YouTube and Twitter). |
Type Of Art | Film/Video/Animation |
Year Produced | 2017 |
Impact | Increased awareness of DPUK and the need for investment new ways of working in dementia research. |
URL | https://www.youtube.com/watch?v=FYlkBpb_D_A |
Title | Animation - 'Introducing Dementias Platform UK' |
Description | This animation has been used on the homepage and About pages of the DPUK website to give the general public an easily accessible overview of Dementias Platform UK aims and work. |
Type Of Art | Film/Video/Animation |
Year Produced | 2017 |
Impact | Our audience research has shown that the general public find this animation useful in understanding the complex DPUK project. |
URL | https://www.dementiasplatform.uk/about |
Title | Cognitive resources leaflet and webpage |
Description | A promotional leaflet designed to direct the target audience of dementia researchers to an information hub with guides and resources for using cognitive data |
Type Of Art | Artefact (including digital) |
Year Produced | 2019 |
Impact | The web pages have received 2,532 visits |
URL | https://www.dementiasplatform.uk/cognition |
Title | DPUK 5 year celebratory event video |
Description | A video round-up of the celebratory event held in September 2019 shared with those invited to attend the event and on social media |
Type Of Art | Film/Video/Animation |
Year Produced | 2019 |
Impact | The video received 102 views on youtube and social media clips of the video uploaded to twitter were viewed 1,567times. |
URL | https://youtu.be/Q9QIhA9Fo8A |
Title | DPUK Linked in profile |
Description | To generate greater engagement with industry DPUK is now as an active Linked In page with regular news updates |
Type Of Art | Artefact (including digital) |
Year Produced | 2019 |
Impact | Following our drive for greater engagement with researchers in industry with an interest in data and dementia we now regularly post updates. We have an engagment rate of 9.39% and have grown followers by 44% in six months. |
URL | https://www.linkedin.com/company/18392913 |
Title | DPUK newsletter (produced 3 times a year) |
Description | The DPUK newsletter is sent three times a year to researchers, related organisations in the dementia research sector, industry companies working in dementia research and development and major funders in the dementia research sector. It features updates on the developments and opportunities in DPUK. |
Type Of Art | Artefact (including digital) |
Year Produced | 2017 |
Impact | Increased awareness of DPUK resources amongst key audience groups: scientists; funders and industry. |
Title | Data Portal communications pack |
Description | This pack was produced an distributed to DPUK's 16 partner organisations (10 universities and 6 pharmaceutical companies) to support the promotion of the Data Portal campaign. |
Type Of Art | Artefact (including digital) |
Year Produced | 2018 |
Impact | 150% increase in traffic driven to DPUK website; increased awareness amongst the dementia research community of DPUK's tools, resources, training and funding opportunities for researchers. |
Title | Data Portal press release |
Description | Press release to all major science publications and science desks of print media at the launch of the DPUK Data Portal. |
Type Of Art | Artefact (including digital) |
Year Produced | 2017 |
Impact | None we are aware of. |
Title | Data Portal resource hub |
Description | Developing a hub of resources and guides that support Data Portal users from applying to analysing data. This resource hub includes fact sheets on using big data, applying for Data Portal data and learning about using the virtual desktop with a synthetic data set. Additionally there are two explainer videos describing how to identify the data you need and analyse it within the virtual desktop |
Type Of Art | Artefact (including digital) |
Year Produced | 2019 |
Impact | The resource page has been visited X times, videos have been viewed X times and the factsheets have been visited 3,521 times |
URL | https://www.dementiasplatform.uk/for-researchers/data-portal-getting-started-with-cohort-data |
Title | Datathon Leaflet |
Description | A highly visual printed promotional postcard for distribution to target audiences at talke, conferences and events to drive recruitment to datathon events in Swansea, Exeter, UEA and Ulster universities. |
Type Of Art | Artefact (including digital) |
Year Produced | 2019 |
Impact | The total number of visitors to the datathon recruitment pages was 828 |
Title | Datathon recruitment web pages |
Description | The datathon pages promote and provide guidance for those interested in joining a datathon workshop. All other datathon communication - leaflets, social media,enews - direct the audience to this hub. |
Type Of Art | Artefact (including digital) |
Year Produced | 2019 |
Impact | Over the course of the year the datathon web hub received 6,728 page views. Social media posts reached 107,073 impressions and resulted in 3,108 engagements Each datathon was fully booked - with a total of 92 attending workshop events |
URL | https://www.dementiasplatform.uk/for-researchers/data-portal-getting-started-with-cohort-data/datath... |
Title | Great Minds animated graphic |
Description | An animated graphic explaining the value of cohort participants to dementia clinical studies and trials. |
Type Of Art | Film/Video/Animation |
Year Produced | 2019 |
Impact | Helped support the recruitment of 45 people to the Great Minds clinical studies register pilot, showing their interest in taking part in future dementia research. |
URL | https://www.youtube.com/watch?v=TTLyYF021uA |
Title | Information sheet |
Description | This information sheet was sent out to our 16 partners (10 partner universities and 6 partner pharmaceutical companies) for inclusion, alongside a news feature, in internal newsletters. |
Type Of Art | Artefact (including digital) |
Year Produced | 2018 |
Impact | Increased engagement from research scientists based at universities and in industry with DPUK's resources on the DPUK website and DPUK Data Portal website. Attendance at DPUK training webinars and expressions of interest/applications for DPUK's 'Discovery Award' funding opportunities for researchers. |
Title | Leaflet |
Description | Leaflet produced for distribution at the Alzheimer's Research UK conference. |
Type Of Art | Artefact (including digital) |
Year Produced | 2017 |
Impact | The leaflet helped to raise awareness amongst the community of dementia researchers of DPUK's free tools and data resources for researchers. |
Title | Leaflet - 2017 |
Description | Leaflet produced for distribution at the Alzheimer's Association International Conference, attended by over 6000 researchers. |
Type Of Art | Artefact (including digital) |
Year Produced | 2017 |
Impact | Increased awareness amongst the dementia research community worldwide about DPUK's tools and data resources for researchers. |
Title | Leaflet - 2018 |
Description | Leaflet included in the Alzheimer's Research UK 2018 conference delegate pack (going to 650 people). |
Type Of Art | Artefact (including digital) |
Year Produced | 2018 |
Impact | At the time of writing the conference itself has not yet taken place. |
Title | MEG & ME |
Description | With ISSF funding, out team held a series of public open evenings to discuss research of interest to the public, to define a sho set of questions and design the experiments to answer them, and then carry it out using MEG. The project was filmed, and presented at a final public discussion meeting at the Cambridge Science Festival |
Type Of Art | Film/Video/Animation |
Year Produced | 2015 |
Impact | The project clearly caught he public's imagination, and over 100 members of the public took part across the weeks. https://vimeo.com/116423919 presents a final summary video |
URL | https://vimeo.com/116423919 |
Title | Magazine article |
Description | John Gallacher was interviewed for this feature in Optima magazine (a lifestyle magazine) about the importance of participation in health research. |
Type Of Art | Artefact (including digital) |
Year Produced | 2017 |
Impact | Feature in Optima magazine. |
URL | http://www.optimamagazine.co.uk/read/style/health/1628-banking-time |
Title | Miscellaneous branded images for DPUK and Dataportal |
Description | Various images, such as the Dataportal background image, genetic computer background and DPUK twitter badge for email signatures. |
Type Of Art | Image |
Year Produced | 2019 |
Impact | - Researchers utilising the Data portal virtual desktop will now have no doubt what they are using - Any press conducted at events such as Datathons, will now capture the DPUK logo on the background of the virtual desktop, instead of the standard windows background. - Traffic is now drawn to the DPUK twitter page each time DPUK staff sends an email. |
Title | Misplaced in Space (September 2017) |
Description | A collaboration with University of East Anglia, to portray the impact of Dementia |
Type Of Art | Artistic/Creative Exhibition |
Year Produced | 2017 |
Impact | A film of the exhibition is available; |
URL | https://vimeo.com/229381641 |
Title | New blog space on DPUK website |
Description | Creating a space for new and relevant content for the target audience where DPUK researchers and partners can outline their research, achievements or experience. |
Type Of Art | Creative Writing |
Year Produced | 2019 |
Impact | New blogs are key content on twitter and LinkedIn for engagement. The are regularly shared on social media. The blog section of the website has been viewed 3,461 times in a year with an average read time of over a minute |
URL | https://www.dementiasplatform.uk/blog |
Title | Social media videos |
Description | Event-based video interviews for release on social media. |
Type Of Art | Film/Video/Animation |
Year Produced | 2019 |
Impact | Ove the past 12 months we have created 45 social media interview videos with a range of DPUK researchers, external ECRs, Senior researchers and Professors and Charity managers. these have been viewed 23,085 times in the past year. Many of these can be seen on our Youtube channel |
URL | https://www.youtube.com/channel/UC9OKgZG5Dq0RheCDV3upakw/videos |
Title | Sound and Vision |
Description | The study is in two parts. The first part consists of interviews between local artists (Visiting Researchers) and service users with a study team member (graduate student) in attendance. Each local artist will be paired with two service users, one recruited from the CPFT clozapine clinic and one recruited from the CUH memory clinic with interviews will take place at the CPFT Tennison Road clinical and at the Herchel Smith Building, respectively. There will be two interviews with each service user, each lasting around an hour. The second part is the attendance of the study team at Science Festivals to display materials and engage the general public to complete on-line questionnaires. Completed artworks will be the centrepiece for an exhibition at UK science festivals and a digital (on-line) presentation. |
Type Of Art | Artistic/Creative Exhibition |
Year Produced | 2022 |
Impact | Website for project detailing output now live following COVID related delays. |
URL | https://soundandvision.org.uk/ |
Title | Study recruitement web page |
Description | A public news and information page designed to allow the public to sign-up to be considered as a participant of a small imaging study. This page was part of a local and media campaign calling for volunteers |
Type Of Art | Artefact (including digital) |
Year Produced | 2020 |
Impact | 27 people registered their interest in participating. |
URL | https://www.dementiasplatform.uk/NTAD |
Title | Video of DPUK conference |
Description | Video of highlights from the DPUK annual conference 2017. |
Type Of Art | Film/Video/Animation |
Year Produced | 2017 |
Impact | Use in the promotion of the 2018 annual conference amongst our key audiences. |
URL | https://www.youtube.com/watch?v=TAsOtdaHkO0 |
Title | Women and girls in sience campaign |
Description | The campaign for Women and Girls in Science day 2020 (11 Feb) included a video of DPUK women researchers describing how working in science is exciting and challenging, a blog from a senior researcher on working in science and having a career break posted on the University of Oxford science blog pages and illustrations of DPUK researchers by illustrator Nina Chhita on Twitter and Instagram. |
Type Of Art | Artefact (including digital) |
Year Produced | 2020 |
Impact | The video and shorter video clips were viewed a total of 3,045 times Oxford Uni Tweeting of the blog received 20 retweets and 105 likes The DPUK social channels gained 38,325 impressions and 511 engagements DPUK Senior researcher's blog on the University of Oxford, Dept Psychiatry and DPUK website was viewed 2308 times |
URL | http://www.ox.ac.uk/news/science-blog/seven-children-20-year-career-break-and-return-cutting-edge-de... |
Description | "Talented Women for a Successful Wales" report commissioned by the Welsh Government |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Participation in a guidance/advisory committee |
URL | http://gov.wales/docs/det/report/160308-women-in-science-en.pdf |
Description | ABN clinical research and academic committee, London representative |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Academy Medical Sciences Council Member |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
Description | Academy Medical Sciences Fellow |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Membership of a guideline committee |
Description | Academy Medical Sciences Wales Ambassador |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
Description | Alzheimer Association Educational Workshop: The basics of fluid biomarkers in AD - speaker |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Alzheimer Disease and APOE genotyping |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Associate Director, UK Dementia Research Institute (UKDRI) |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Membership of a guideline committee |
Description | Attend technical meeting on the Implementation of the Global Action Plan on Public Health Response to Dementia |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Attendance to TRC-D Steering Committee Meeting |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
URL | https://www.nihr.ac.uk/partners-and-industry/industry/collaborate-with-us/dementia.htm |
Description | Attended Association of British Neurologist's annual conference and delivered citation for ABN medallist |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Description | COVID advisory group |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
Description | Calman Training |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Influenced training of practitioners or researchers |
Description | Canadian Consortium on Neurodegeneration in Aging (CCNA) |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Chief Scientific Advisor to Alzheimer's Research UK |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Chief Scientific Advisor, Welsh Government |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Membership of a guideline committee |
Description | Clinical Expert for a NICE Scientific Advice consultation on Alzheimer's Disease |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Contributor to a review of current dementia recruitment registers and its role for the public and research landscape |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
Description | DPUK2Associate Director |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | DPUK is leading academic-industrial partnerships for dementia research, and coordinating the 'ecosystem' for dementia research and care in the UK. As associate Director and lead for Experimental Medicine, my role is to accelerate early phase clinical trials though partnerships with industry, academic and third-sector stakeholder collaborations |
URL | https://www.dementiasplatform.uk/ |
Description | Dementia Programme Board - oversee the implementation of the PM's Challenge on Dementia to 2020 |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Dementia Research Institute VIP Visit |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Description | Deputy Chair, ABN Cognitive Disorders Advisory Group |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | N/A |
Description | Deputy Director DPUK |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Membership of a guideline committee |
Description | Dr H Fye - University of Cambridge Research Culture Steering Committee Member |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Contribution to new or improved professional practice |
Impact | Tbc |
Description | Dr M Malpetti - Invited contribution to the World Alzheimer Report 2021 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | Publication to serve as reference for students and practitioners. |
URL | https://www.alzint.org/u/World-Alzheimer-Report-2021.pdf |
Description | Dr M Perquin (Rowe Group) Member Society for Mathematical Psychology |
Geographic Reach | Europe |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | Dr M Perquin (Rowe Group) Member Society for Mathematical Psychology |
Description | Dr M Perquin (Rowe Group) Member Women of Mathematical Psychology |
Geographic Reach | Europe |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | • Became member of the professional organisation Women of Math Psych. |
Description | EPAD LCS sample access committe |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Membership of a guideline committee |
Description | Expert in government-supported monthly ADD Chip 5m cohort meetings |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | John Gallacher is a regular expert at monthly ADD Chip design meetings - a group which aims to form a cohort [supported by the UK Government, Charities and Industry (pharma, diagnostic & digital)] which looks to create the largest risk stratified population (including by genotype) in the world. It wants to involve 5 million healthy individuals, aged 40-75. Recent successes include ADD now being set up as a company limited by guarantee with one employee (Interim COO FR). CEO interviews have taken place and CEO could be in post as early as April. CRUK to host the CEO for the first year until the company has physical premises. |
Description | German Centre for Neurodegenerative Diseases (DZNE) scientific review |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Invitation to participate in Challenge on Dementia 2020 workshop - May 2019 |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
Impact | John was personally invited to participate in a working group on research and funding as part of the government's review of the Challenge on Dementia 2020 on the afternoon of Friday 24th May. Earlier in 2019, the government published a report summarising the views of stakeholders on the progress of the Challenge on Dementia so far and set out actions for the remaining 2 years of the Challenge. The government is also looking beyond 2020 and invited stakeholders to identify priorities for a post-2025 strategy. As part of this work DHSC are facilitated 5 working groups to consider a maximum of 3 recommendations for each group. The 5 working groups will cover: 1. Technology 2. Research/funding 3. Dementia awareness 4. Risk reduction 5. Health and care delivery Martin Rossor and Hilary Evans were asked to chair the research/funding working group which will took place on Friday 24th May from 2pm-5pm in Conference Room 1, DHSC, 39 Victoria Street, London. John was asked to join these discussions and to help consider which 3 recommendations are priorities for the field to help us move the research forwards towards effective treatments. |
URL | https://www.gov.uk/government/publications/prime-ministers-challenge-on-dementia-2020 |
Description | Invited abstract reviewing board member at Tau2022 conference - Dr M Malpetti |
Geographic Reach | Europe |
Policy Influence Type | Membership of a guideline committee |
Impact | Served as subject specific reviewer. |
Description | Invited abstract reviewing board member at the European Molecular Imaging Meeting - Dr M Malpetti |
Geographic Reach | Europe |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | Served as subject specific reviewer. |
Description | Invited as expert to contribute to discussion with Chris Whitty, Chief Scientific Adviser, Department of Health and Social Care re: polygenic testing to improve health |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
Impact | A draft final integrated table has been created, incorporating all inputs received, for Polygenic Risk Sscore performance for different diseases (integrated updated online version here: https://docs.google.com/spreadsheets/d/1XFbVkjpNeNexH6NvWzEcrQIF88ogQ9b6NPXy-FfeOCI/edit?usp=sharing). This table also includes the PRS generated by Genomics PLC across a number of disorders including their validations from UKBiobank. Albeit that we have amassed some very useful starter data on the spreadsheet, given the rich and diverse debate generated by this process, it seems the exam question we were set by Chris is far from answered. The next steps could be to: (i) agree a 'short-list' of conditions as being the currently most plausible (ii) examine in detail existing analyses for clinical impact and health economic impact for these disease use-cases (iii) evaluate predicted trajectory of PRS with future GWAS (ie what will PRS do in 5,10,15 years with delivery from additional GWAS) (iv) current research priorities for PRS evaluation/implementation. Breast Cancer, Coronary Artery Disease and ?colorectal cancer likely remain front-runners (driven primarily by population incidence). It was discussed whether further dialogue is warranted, and if so, what would be the best way of continuing it and bringing in those with the requisite focused expertise? For example, potentially another modest-sized closed meeting: delineated data-driven sessions focused on really unpicking health utility/specific diseases use cases and ways forwards. |
URL | https://www.gov.uk/government/people/christopher-whitty |
Description | Invited co-authorship for a systematic review - Dr M Malpetti |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Contribution to new or Improved professional practice |
Impact | Publication in a major journal. |
Description | Invited contribution to hot-topic series for the Journal of Nuclear Medicine - Dr M Malpetti |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Contribution to new or Improved professional practice |
Description | Invited leading figure to UK Dementia Ecosystem Summit (hosted by UK DRI) |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
Impact | John Gallacher was invited as a leading figure in dementia to invite to participate in a small meeting with other leaders of the UK Dementia Ecosystem to be held towards the end of March in central London. The meeting was an opportunity for him and other leaders to inform each other of their goals and aspirations, identify possible areas of synergy and collaboration and discuss the most pressing issues. Goals and achievements for the meeting included: Promote awareness of vision and goals of each participating organisation. - Define potential points of synergy and collaboration in the short, medium and long term, particularly in the following areas: • Development of tools for translational research and experimental medicine • Understanding the breadth of symptoms that make up the spectrum of dementia: communication between basic and clinical science • Care research and technology - Define a clear message engaging the Government to sustain dementia research. |
URL | https://ukdri.ac.uk/news-and-events/dementia-ecosystem-uk-action-through-alliance |
Description | Invited to review Clinical Trials Regulation by Medicines and Healthcare products Regulatory Agency (MHRA) |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | This policy review has been launched following the United Kingdom's departure from the European Union. It aims to design a world-class sovereign regulatory environment for clinical trials that will support the development of innovative medicines and ensure that the UK retains and grows its reputation as world leading base for life sciences, generating opportunities for skilled jobs in the UK. |
Description | JGallacher contribution to IHCC Policy Working Group |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | John Gallacher contributed to the discussion surrounding streamlining policy development for the IHCC strategy. IHCC aims to create a global platform for translational research - informing the biological and genetic basis for disease and improving clinical care and population health. It includes the opinion of the PIs of the top 100 largest cohorts globally, so includes the work of DPUK. |
URL | https://ihccglobal.org/ |
Description | JGallacher contribution to Our Future Health Design Group monthly meeting |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | JGallacher contribution to the design of one of the UK's largest cohort studies involving members of the public, including the application of online cognitive tests. Our Future Health will be the UK's largest ever health research programme, designed to help people live healthier lives for longer through the discovery and testing of more effective approaches to prevention, earlier detection and improved treatment of diseases. |
URL | https://www.closer.ac.uk/event/our-future-health/ |
Description | JGallacher contribution to Register of Registers meeting - streamlining national efforts to recruit to dementia studies |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | JGallacher contribution to Register of Registers meeting - streamlining national efforts to recruit to dementia studies in order to remove barriers to members of the public and those part of cohort studies to sign up to research efforts. The meeting was attended by several register keepers and PIs to agree eg that the CSR/Great Minds effort should be listed on the Join Dementia Research webpage for improved visibility. |
URL | https://www.greatmindsfordementia.uk/dementias-platform-uk |
Description | JPND SAB Meeting - re-launching its Strategic Research and Innovation Agenda (SRIA) |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Keynote presentation on DPUK at Westminster Health Forum policy conference - 'Improving dementia outcomes in England: research, personalised care and health and social care integration' |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | The agenda: Progress on meeting the goals of the Dementia 2020 Challenge and priorities for moving forward post-2020; Developing an integrated approach to improving dementia outcomes in Birmingham; Integrating health and social care - workforce development, creating dementia-friendly communities and the role of technology; Personalised care in practice - addressing barriers, increasing access and supporting patient choice; Key issues for regulating dementia services; Next steps for dementia research - funding, translating research into practice and improving patient participation: Supporting research to improve dementia outcomes; Data in the digital age for dementia research: Dementias Platform UK; Collaboration with industry partners: and Encouraging the translation of research into clinical practice. |
URL | https://www.westminsterforumprojects.co.uk/publication/dementia-care-in-England-19 |
Description | Long-term and regular involvement in the IHCC Policy Working Group |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | John is a representative on the Policy team (Team C) for the formation of the International Hundred K+ Cohorts Consortium (IHCC). The IHCC represents the 100 largest cohorts globally (mostly those who include over 100k participants) and aims to improve the work of cohorts on an international scale,. IHCC have facilitated discussions on improving prospects for compatibility of cohort elements (e.g., instruments, data formats, phenotype measures, & consents), promoting data and specimen sharing & open access policies, examining potential for collaborative genome sequencing/analysis, and exploring feasibility of a searchable global cohort registry. The overall charge of the Policy Team is to create a policy agenda to facilitate and optimise impact of assembling cohorts. A draft IHCC Guidance for Collaboration with Industry has been created, with thoughts of also producing a publication. |
URL | https://ihcc.g2mc.org/teamc/ |
Description | MRC Dementias Platform UK 'Open Science Champion' and Steering Group member |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
URL | http://www.mrc.ac.uk/research/facilities-and-resources-for-researchers/dementias-platform-uk/governa... |
Description | Medicines Discovery Institute MDI |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
Description | Member of the Bevan Commission Working Group |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Member, Biobank access committee, Brains for Dementia Research |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | NMHRI management |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
Description | OLS-DIG Dementia scoping |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
Impact | Decision taken to establish the Neurodegeneration initiative within the Dame Barbara Wilson Dementia Mission |
Description | Organising committee member AAIC Neurosciences Next - Dr M Malpetti |
Geographic Reach | North America |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | Postgraduate training |
Description | Participation as expert in Population Research Resource landscape review - November 2019 |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
Impact | John was invited as expert to comment on a landscape review and lessons learnt document from existing population research resource initiatives. Wellcome is working with the MRC and the ESRC to identify what kind of new Population Research Resource is required to capitalise on the rich longitudinal data and biological samples from the wealth of UK large-scale, long-term population based studies (including cohort studies). Their focus is on enabling cross-study research through the discoverability and sharing of longitudinal data and samples, linking these data with administrative, health and other routine records, and encouraging best practice. At the Population Research Resource Workshop held on the 24th May 2019 (which John also participated) a list of existing initiatives that support longitudinal population studies in the UK were identified, along with a list of functions that these initiatives may provide. Wellcome have now commissioned to write a short report by November 29th 2019 to provide them with a description and "lessons learnt" review of these existing initiatives. The first stage of the review was to provide a one-page summary of existing initiatives from publically available information on the websites of these initiatives that describes the resource, its purpose and objectives, and the functions provided. The second stage of the review was to contact the lead of each initiative by email to obtain further information to clarify these summaries that will form an appendix in the report. John completed an in-depth questionnaire and 1:1 interview on his view of the landscape. |
Description | Participation in an advisory committee - Alzheimer Research UK Scientific Advisory Board Chair (2021) |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | ARUK is a major funder of Alzhiemer's disease related research in the UK. Serving as chair on this advisory board has had a significant impact in helping ARUK direct their funding towards areas of greatest impact, as well as helping researchers build effective collborations resulting in meaningful insights improving patient care and informing policy. |
Description | Press conference |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Influenced training of practitioners or researchers |
Description | Proposal sent to UK Biobank titled 'Proposal: Subjective memory questions in UK Biobank' |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Description | Proposal to UK Biobank titled 'Proposed cognitive tests for an enhanced UK Biobank cognitive battery' |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Description | Reinvigorating health registries during COVID for rapid policy analyses |
Geographic Reach | Europe |
Policy Influence Type | Participation in a guidance/advisory committee |
URL | https://www.registerkonferansen.no/ |
Description | Report sent to UK Biobank titled 'Observation of the enhanced UK Biobank cognitive assessment' |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Description | Report sent to UK Biobank titled 'Recommendations on the retention of cognitive tests in the UK Biobank cognitive test battery' |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Description | Report to UK Biobank on the UK Biobank cognitive assessment titled 'Test characteristics of the enhanced UK Biobank Cognitive Assessment' |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Description | Representative on SAIL Databank Scientific External Advisory Board (Dec 2019) |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | The SAIL Scientific External Advisory (SEA) Board discussed and generated actions in relation to topics such as new data types / usages and resulting information governance challenges; Data proportionality v. the demand for programme level data, and Development of a Public Involvement & Engagement policy/strategy for SAIL. |
URL | https://saildatabank.com/ |
Description | Sceintific Advisory Board Meber for AI-MIND |
Geographic Reach | Europe |
Policy Influence Type | Influenced training of practitioners or researchers |
URL | https://www.ai-mind.eu/partners/ |
Description | Speaking at ARUK Policy conference: Looking forward: Towards dementia treatment - planning for the requirements to deliver new treatments for AD in the UK |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Standard Operating Procedures sent to UK Biobank - SOPs for IQCODE |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Description | Talk at International Cohorts Summit, Iceland - April 2019 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | IHCC convened the second International Cohorts Summit in Reykjavik, Iceland April 2019 with the intent of developing the scientific agenda to drive the research and collaboration between cohorts and present Team activities and progress on goals that were established as the result of the first International Cohorts Summit held in March 2018. The primary objectives of this meeting were to: Identify scientifically meritorious cross-cohort research projects and identify international collaborators willing to organize and participate in them Develop an IHCC scientific agenda to bring forward to funding bodies The International Cohorts Summit was conceived by the Heads of International Research Organizations (HIROs) chaired by Jeremy Farrar of the Wellcome Trust, with an inaugural summit held in March 2018 in Durham, North Carolina, USA, organized by the Global Genomic Medicine Collaborative (G2MC), with the goal of enabling leaders of large-scale longitudinal cohorts worldwide to share best practices, discuss data sharing, explore standards, discuss common challenges, and explore the potential for a large(r) collaborative sequencing strategy. From that Summit, the International HundredK+ Cohorts Consortium (IHCC) was formed, with teams assembled to address the actions identified in this Summit. John Gallacher was invited to contribute alongside the PIs of the most influential cohorts and their funders internationally to discuss remedies to challenges and opportunities faced by cohorts. This particular summit involved giving a pitch by Dr Sarah Bauermeister on behalf of Team C's work on policy. The pitch was on a precision medicine approach to multi-morbidity in cardio-metabolic disease and dementia, and the resources required for this. The DPUK Data Portal was demonstrated as a world-leading tool in data curation and analysis instrumental to the cause. Sarah was approached several times from international funding and policy leaders in the field, and engaged for further collaboration. One major impact was an invitation from China to attend a workshop discussing how DPUK and the Data Portal could aid research in Asia. |
URL | https://ihcc.g2mc.org/ics2019/ |
Description | The Secure Anonymised Information Linkage System |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | UCL ageing event - cultivating research connections across the university: organising committee and plenary speaker |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | UK Biobank - long-term and regular attendance as a representative on the UKB Steering Committee |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | John is a long-term and regular representative at the tri-annual UKB steering committee meetings in London, as well as UKB's annual International Scientific Advisory Board. John provides expertise and leadership on cognitive and psychological assessments. His work for UK Biobank provides a regular touch-point for DPUK, with the platform benefiting from John's detailed and up-to-date knowledge UKB's resources and direction. |
URL | https://www.ukbiobank.ac.uk/steering-committee/ |
Description | UK representative - European Academy of Neurology Dementia Panel |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Vice Chair and Chair Elect, Advisory Council US Alzheimer's Association ISTAART |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Membership of a guideline committee |
Description | WHO's Global Dementia Observatory discuss the implementation of the global action plan on public health response to dementia 2017-2025 |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
Description | Work group to establish a Danish brain research centre - Lundbeckfonden, The Brain Prize |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Working Group Lead on Emeritus Professor John Bell's response to potential increase in Dementia governmental funding |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | Following a recent a Conversative goverment pledge (https://www.bbc.co.uk/news/election-2019-50523507), it is anticipated that there will be significant new UK Government funding for dementia research. As additional funding will probably be focussed in areas identified as particularly challenging to drug discovery, it will probably leverage in considerable matched, pre-competitive industry funding. Further, it is likely that this investment will be in translational research - complementing existing Dementia Research Institute activity in basic research. In the -omics era major discoveries driven by genomics, proteomics and metabolomics have uncovered the key protein pathways, cellular pathology within the brain and the systemic effects of the disease involving the vascular system and the gut-liver-brain axis. In next decade, bridging the gap between target discovery and clinical interventions is one of the major challenges. The interest of industry appears to be focussed on target validation and human experimental medicine. To make a strong Oxford offer, it was proposed to need to take stock of current strengths and identify key gaps. It was thought this relevant work in Oxford takes place across multiple Departments and will require coordination, as will the relevant infrastructure. This aim of this workshop was to develop Oxford's strategy for expanding dementia research, maximising the potential for both local research and for collaborations with national programmes including the Dementia Research Institute (DRI), Dementia Platform UK (DPUK) and ARUK Drug Discovery Institutes (DDI). The three major areas of focus for the meeting included target discovery and validation; Big Data and multi-omics data integration, and Experimental Medicine. As a result of the meeting, John Gallacher was asked to be chair of one of the four working groups ('Biobanks/Clinical follow-up studies/Epidemiology'). A decision was taken to build Oxford's translational research offering in dementia to a higher level allowing Oxford to secure transformational funding in the £50m+ range from industry, government and philanthropic sources. Each group was asked to: i) map current landscape ii) map future landscape required iii) identify capability gaps. iv) Propose how we can fill capability gaps and outline a. the required capability i.e. new posts, new equipment, shared resources, new/existing technology, new approaches etc. b. the resources/funding required. c. a timeline e.g. if recruitment is required for a strategic appointment or new equipment is ordered/infrastructure built In a document structured as suggested above. John's working group was asked to identify a clinical lead seeing patients in Oxford to:- a. Ensure we are biobanking rich patient material in Oxford (CSF, skin biopsies etc..) b. Build up our UK clinical network in advance of the bid with inter-institutional alliances to complement our translational offering. A revised draft of a white paper is being produced, setting out the overall scientific vision. The more detailed granular output of the working groups will be fed into this i.e. the additional capability building required, resources necessary and implementation timeline. |
Description | World Dementia Council |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | "A multi-centre randomised controlled trial of the clinical and cost-effectiveness of sertraline in preventing depression in adults following a traumatic brain injury" |
Amount | £1,988,751 (GBP) |
Organisation | NIHR London (South) CRN |
Sector | Public |
Country | United Kingdom |
Start | 08/2021 |
End | 08/2024 |
Description | "Clinician training partnership: vascular contribution to dementia": Clinical Training Partnership awarded to W Whiteley, JM Wardlaw, G Hardingham, CW Ritchie, C Smith, A Williams, K Horsburgh, H Whalley, S Munoz Maniega |
Amount | £225,000 (GBP) |
Funding ID | 3699 |
Organisation | Alzheimer's Society |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 07/2022 |
Description | "Dementias Platform UK" Co-applicant with principal applicant John Gallacher (Oxford) and co-applicants Ronan Lyons, James Rowe, Carol Routledge, Declan Jones |
Amount | £7,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2021 |
End | 12/2025 |
Description | "Integrative imaging of brain structure and function in populations and individuals" (awarded to Mark Woolrich) |
Amount | £570,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2020 |
End | 12/2024 |
Description | "Small Vessel Disease - Spotlight on Symptoms (SVD-SOS) - Improving recognition of symptoms and signs of progressing cerebral small vessel disease-related brain damage to prevent cognitive decline, dementia and stroke" (Doubal F, Wardlaw, JM) |
Amount | £24,962,394 (GBP) |
Funding ID | SA PG 19\100068 |
Organisation | Stroke Association |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 07/2022 |
Description | "Synaptic Health In Neurodegeneration" PI Prof James B Rowe Co-applicants Kia Nobre and Mark Woolrich |
Amount | £400,000 (GBP) |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 09/2021 |
End | 09/2024 |
Description | "UK DRI IPSC platform to model Alzheimer's disease risk (IPMAR) " |
Amount | £1,866,149 (GBP) |
Organisation | UK Dementia Research Institute |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2021 |
End | 07/2023 |
Description | "Wellcome Centre for Integrative Neuroimaging" (awarded to Kia Nobre and Mark Woolrich) |
Amount | £2,801,188 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2022 |
End | 03/2024 |
Description | 1946 ARUK |
Amount | £1,824,093 (GBP) |
Funding ID | ARUK-PG2014-1946 |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2014 |
End | 06/2017 |
Description | A longitudinal amyloid-PET/MRI study of the 1946 birth cohort. ARUK-PG2017-1946. |
Amount | £1,216,062 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2017 |
End | 06/2019 |
Description | A standardized, multilingual, mini linguistic state examination (MLSE) for classifying and monitoring primary progressive aphasia. |
Amount | £358,924 (GBP) |
Funding ID | RG82683 |
Organisation | St George's University |
Sector | Academic/University |
Country | Grenada |
Start | 01/2017 |
End | 12/2019 |
Description | A*-STAR Scholarship (Supervisor to Quyen Do). Advanced 3D co-culture iPSC-derived models of Parkinson's |
Amount | $206,382 (SGD) |
Organisation | Agency for Science, Technology and Research (A*STAR) |
Sector | Public |
Country | Singapore |
Start | 01/2018 |
End | 09/2022 |
Description | ABBUK Brains for Dementia Research Programme (extension) |
Amount | £404,390 (GBP) |
Funding ID | 504291 |
Organisation | Alzheimer’s Brain Bank UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2013 |
End | 03/2018 |
Description | ABBUK Brains for Dementia Research Programme (extension) |
Amount | £2,598,988 (GBP) |
Organisation | Alzheimer’s Brain Bank UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2021 |
Description | ARUK East Network Travel Grant - Dr M Malpetti |
Amount | £1,000 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2022 |
Description | ARUK Illustration Award 2021 given to Bryan Ng |
Amount | £200 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2021 |
End | 08/2021 |
Description | ARUK Illustration Award 2023 given to Ajantha Abey |
Amount | £200 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2023 |
End | 05/2023 |
Description | ARUK Illustration Award 2023 given to Rachel Heon Roberts |
Amount | £200 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2023 |
End | 05/2023 |
Description | ARUK ODDI collaboration: Phenotypic drug discovery in Parkinson's |
Amount | £200,000 (GBP) |
Organisation | University of Oxford |
Department | Alzheimer's Research UK Oxford Drug Discovery Institute |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2017 |
End | 12/2020 |
Description | ARUK Oxford Pilot Investigating the effect of tau on axonal transport and tau release in MAPT-iPSC cortical neuron models |
Amount | £4,000 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | ARUK Oxford Pilot Optogenetic light source and controller for 96/384-well plates to allow uniform illumination of wells inside a cell-culture incubator. |
Amount | £4,000 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | ARUK Pilot Analysis of tau secretion in iPS differentiated neuronal cultures |
Amount | £4,000 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | ARUK Pilot Award 2020-21 given to Dr Charmaine Lang & Mr Peter Kilfeather |
Amount | £2,297 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2021 |
End | 08/2021 |
Description | ARUK Pilot Award 2020-21 given to Maria Claudia Caiazza |
Amount | £2,500 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2021 |
End | 08/2021 |
Description | ARUK Thames Valley Illustration Award 2023 |
Amount | £250 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2023 |
End | 02/2023 |
Description | ARUK Thames Valley Network Pilot Award 2022 |
Amount | £2,000 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2022 |
End | 12/2023 |
Description | ARUK Thames Valley Network Travel Award for Becky Carlyle |
Amount | £168 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2022 |
End | 12/2022 |
Description | ARUK Thames Valley Network Travel Award for Brent Ryan to attend two conferences |
Amount | £54,095 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2022 |
End | 12/2022 |
Description | ARUK Thames Valley Network Travel Award for Helle Barknob |
Amount | £138 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2022 |
End | 12/2022 |
Description | ARUK Thames Valley Network Travel Award for Hugo Fernandes |
Amount | £211 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2022 |
End | 02/2023 |
Description | ARUK Thames Valley Network Travel Award for Maria Claudia Caiazza |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2022 |
End | 12/2022 |
Description | ARUK Thames Valley Network Travel Award for Rachel Heon Roberts |
Amount | £600 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2022 |
End | 01/2023 |
Description | ARUK Thames Valley Network Travel Award for William McGuinness |
Amount | £500 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2022 |
End | 01/2023 |
Description | ARUK Thames Valley Network travel award: Mootaz Salman |
Amount | £600 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2022 |
End | 12/2023 |
Description | ARUK Travel Award 2020-21 given to Kaitlyn Cramb to attend & present at AD/PD conference in Barcelona |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2022 |
End | 03/2022 |
Description | ARUK Travel Award 2020-21 given to Martha Lavelle |
Amount | £100 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2021 |
End | 09/2021 |
Description | ARUK Travel Award 2020-21 given to Quyen Do to attend Ion channels in Synaptic and Neural Circuit Physiology online conference |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2021 |
End | 06/2021 |
Description | ARUK Travel Award given to Ajantha Abey to attend ARUK Early Careers Day and Research Conference 2022 |
Amount | £126 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2022 |
End | 03/2022 |
Description | ARUK Travel Award given to Ajantha Abey to attend ARUK Early Careers Day and Research Conference 2023 |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2023 |
End | 03/2023 |
Description | ARUK Travel Award given to Akansha Mehta to attend ARUK Research Conference 2023 |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2023 |
End | 03/2023 |
Description | ARUK Travel Award given to Bryan Ng to attend ARUK Early Careers Day and Research Conference 2022 |
Amount | £205 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2022 |
End | 03/2022 |
Description | ARUK Travel Award given to Charmaine Lang to attend ARUK Research Conference 2023 |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2023 |
End | 03/2023 |
Description | ARUK Travel Award given to Gizem Onal to attend ARUK Research Conference 2023 |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2023 |
End | 03/2023 |
Description | ARUK Travel Award given to Jonah-Wolf Schreier to attend ARUK Research Conference 2023 |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2023 |
End | 03/2023 |
Description | ARUK Travel Award given to Kaitlyn Cramb to attend Federation of European Neuroscience Societies Regional Meeting 2023 |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2023 |
End | 05/2023 |
Description | ARUK Travel Award given to Maria Claudia Caiazza to attend AD/PD conference 2022 |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2022 |
End | 03/2022 |
Description | ARUK Travel Award given to Maria Claudia Caiazza to attend Parkinson's Disease Theme ECR workshop Meeting 2023 |
Amount | £204 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2023 |
End | 03/2023 |
Description | ARUK Travel Award given to Mootaz Salman to attend ARUK Research Conference 2023 |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2023 |
End | 03/2023 |
Description | ARUK Travel Award given to Mootaz Salman to attend Brain 2022 |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2022 |
End | 07/2022 |
Description | ARUK Travel Award given to Nancy Ahuja to attend ARUK Research Conference 2023 |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2023 |
End | 03/2023 |
Description | ARUK Travel Award given to Naroa Ibarra Aizpurua to attend UKDRI - Parkinson's Disease Theme ECR Workshop 2023 |
Amount | £96 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2023 |
End | 03/2023 |
Description | ARUK Travel Award given to William McGuinness to attend AD/PD conference 2022 |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2022 |
End | 03/2022 |
Description | ARUK Travel grant |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 08/2019 |
Description | ARUK network pilot grant |
Amount | £5,000 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2019 |
Description | Addenbrooke's Charitable Trust |
Amount | £59,172 (GBP) |
Organisation | Addenbrooke's Charitable Trust (ACT) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2023 |
End | 03/2024 |
Description | Addenbrooke's Charitable Trust |
Amount | £59,172 (GBP) |
Organisation | Addenbrooke's Charitable Trust (ACT) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2023 |
Description | Airwave Health Monitoring Study (AHMS) |
Amount | £23,908 (GBP) |
Funding ID | WPEA_P72447 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 06/2020 |
End | 06/2023 |
Description | Ajantha Abey, The Clarendon Fund & Department of Physiology, Anatomy, and Genetics Scholarship. Project title: Understanding Selective Neuronal Vulnerability in Alzheimer's and Parkinson's Disease and Potential Remedies Through Patient-Derived Stem-Cells |
Amount | £125,097 (GBP) |
Organisation | University of Oxford |
Sector | Academic/University |
Country | United Kingdom |
Start | 09/2020 |
End | 09/2023 |
Description | Alzheimer's Disease Data Enablement Fund sponsored project: Traumatic brain injury, emotional adversity and the long-term effects on adult outcomes and dementia. |
Amount | £612,845 (GBP) |
Organisation | National Philanthropic Trust |
Sector | Charity/Non Profit |
Country | United States |
Start | 03/2019 |
End | 12/2019 |
Description | Alzheimer's Research UK East Network Grant |
Amount | £913 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2023 |
End | 07/2023 |
Description | Autophagic flux |
Amount | £317,137 (GBP) |
Organisation | Michael J Fox Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 08/2017 |
End | 08/2019 |
Description | Awarded an Oxford ARUK Small Equipment Award to purchase an Oxford Nanopore MinION |
Amount | £3,670 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2019 |
End | 07/2019 |
Description | BHF Research Excellence Award |
Amount | £3,000,000 (GBP) |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2019 |
End | 04/2024 |
Description | BRC award to UCL/H (Dementia Theme) |
Amount | £5,000,000 (GBP) |
Organisation | National Institute for Health Research |
Department | NIHR Biomedical Research Centre |
Sector | Public |
Country | United Kingdom |
Start | 03/2017 |
End | 04/2022 |
Description | Becky Carlyle - Subcellular proteomic signatures of Alzheimer's disease. |
Amount | $64,000 (USD) |
Organisation | National Institutes of Health (NIH) |
Sector | Public |
Country | United States |
Start | 01/2022 |
End | 12/2024 |
Description | Bioinformatics and Functional Genomics |
Amount | £1,250,000 (GBP) |
Organisation | UK Dementia Research Institute |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2023 |
End | 03/2028 |
Description | Biomedical Research Centre Dementia Theme |
Amount | £118,000,000 (GBP) |
Funding ID | RG85367 |
Organisation | National Institute for Health Research |
Department | NIHR Biomedical Research Centre |
Sector | Public |
Country | United Kingdom |
Start | 03/2017 |
End | 03/2022 |
Description | Blood-based fingerprints of neuroinflammation in people with PSP and CBD - Dr M Malpetti (Rowe Group) |
Amount | $98,735 (USD) |
Funding ID | Research Grant 689-2024-01-Pipeline |
Organisation | CurePSP, Inc. |
Sector | Charity/Non Profit |
Country | United States |
Start | 03/2024 |
End | 05/2026 |
Description | Brain Network Analysis in Neurodegenerative Tauopathies |
Amount | £22,391 (GBP) |
Funding ID | RG89925 |
Organisation | The Evelyn Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2018 |
End | 12/2019 |
Description | Brain Research Trust |
Amount | £219,355 (GBP) |
Organisation | Brain Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2016 |
End | 03/2019 |
Description | Brain Research Trust |
Amount | £219,355 (GBP) |
Organisation | Brain Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2016 |
End | 03/2019 |
Description | Brains for Demention Research Programme |
Amount | £225,571 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2013 |
End | 03/2018 |
Description | Bridging the gap: biophysical models of human frontotemporal lobar degeneration |
Amount | £2,025,694 (GBP) |
Funding ID | 220258/Z/20/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2021 |
End | 03/2026 |
Description | British Heart Foundation - Cardiovascular mechanisms linked to cerebral amyloid b deposition and cognitive decline: a sub study of INSIGHT 46 |
Amount | £273,844 (GBP) |
Funding ID | PG/17/90/33415 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2018 |
End | 04/2022 |
Description | British Heart Foundation - NIHR - Bloomsbury Centre for clinical phenotyping (BBCP): infrastructure Grant |
Amount | £776,285 (GBP) |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2019 |
End | 12/2019 |
Description | Centre for Ageing and Dementia Research (CADR) |
Amount | £386,341 (GBP) |
Organisation | Welsh Assembly |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | Cerebrovascular health in older adults at a genetic risk for dementia |
Amount | £3,970 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2018 |
End | 08/2018 |
Description | Clinical research infrastructure |
Amount | £1,500,000 (GBP) |
Organisation | University of Cambridge |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2016 |
End | 03/2016 |
Description | Clinical research infrastructure |
Amount | £6,995,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 08/2015 |
End | 09/2020 |
Description | Collaborative award: Integrative imaging of brain structure and function in populations and individuals. Co-applicant with lead applicant Stephen Smith, Saad Jbabdi, Mark Jenkinson, Karla Miller (University of Oxford), Christian Beckmann (Radboud) |
Amount | £4,106,203 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2020 |
End | 12/2025 |
Description | Compartmentalised calcium handling in dopamine neurons: importance for selective vulnerability in Parkinson's. |
Amount | £3,700,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2022 |
End | 04/2027 |
Description | DRI Costs |
Amount | £1,123,799 (GBP) |
Organisation | UK Dementia Research Institute |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2017 |
End | 08/2022 |
Description | Dayne Beccano-Kelly Lockey Fund- for travel to World Parkinson's congress |
Amount | £500 (GBP) |
Organisation | Lockey Committee |
Sector | Academic/University |
Country | United Kingdom |
Start | 02/2019 |
End | 04/2019 |
Description | Deconvoluting the dementia phenotype using functional genomics and computational approaches |
Amount | £537,913 (GBP) |
Organisation | Government of Wales |
Department | Welsh European Funding Office |
Sector | Public |
Country | United Kingdom |
Start | 01/2018 |
End | 10/2022 |
Description | Deep and Frequent Phenotyping; combinatorial biomarkers for dementia experimental medicine |
Amount | £8,101,701 (GBP) |
Funding ID | MR/N029941/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2016 |
End | 09/2025 |
Description | Dementias Platform |
Amount | £6,618,190 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 05/2014 |
End | 06/2019 |
Description | Dept MRC Studentship (Principal Supervisor to Naroa Ibarra Aizpurua, Co-supervisor Dr Sally Cowley; Understanding the contribution of astrocytes to Parkinson's. |
Amount | £15,900 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2020 |
End | 09/2022 |
Description | Developing new therapeutic drugs in pre-clinical models of Parkinson's. |
Amount | $200,000 (USD) |
Organisation | Michael J Fox Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 06/2021 |
End | 02/2023 |
Description | Dr Andrea Loreto Sir Henry Wellcome postdoctoral fellowship. Project title: The role of the Wallerian axon-death pathway in neuronal and axonal vulnerability in Parkinson's disease |
Amount | £250,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2021 |
End | 04/2022 |
Description | Dr Becky Carlyle: Exploiting sub-cellular proteomics and high-throughput validation screens to define the role of proteome complexity in Alzheimer's Disease |
Amount | £420,000 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2022 |
End | 09/2025 |
Description | Dr Charmaine Lang & Mr Peter Kilfeather were awarded an ARUK Thames Valley Pilot Award |
Amount | £2,297 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2021 |
End | 06/2021 |
Description | Dr Mootaz Salman was awarded an ARUK Thames Valley Network Small Equipment Award 2020 |
Amount | £2,000 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 12/2020 |
End | 03/2021 |
Description | Dr Phillipa Carling was awarded an ARUK Thames Valley Network ECR award |
Amount | £349 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2020 |
End | 12/2020 |
Description | Dr Sally Cowley Co-Investigator. Establishing a platform in human iPS-macrophages for interrogation of the STING pathway in Parkinson's. |
Amount | £123,000 (GBP) |
Organisation | Michael J Fox Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start |
Description | Dr Sally Cowley Co-applicant/Co-supervisor. Targeting crosstalk between microglia, astrocytes and neurons in Alzheimer's disease pathology |
Amount | £500,000 (GBP) |
Organisation | Eli Lilly & Company Ltd |
Sector | Private |
Country | United Kingdom |
Start |
Description | Dr Stefania Giussani was awarded an ARUK Thames valley network ECR Award |
Amount | £493 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2020 |
End | 12/2020 |
Description | Drake Foundation: Effects of head injury the NSHD 1946 birth cohort. |
Amount | £60,852 (GBP) |
Organisation | The Drake Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2017 |
End | 04/2019 |
Description | Drake Foundation: Head Injury, cognition and imaging correlates of dementia in the Insight 46 cohort |
Amount | £60,852 (GBP) |
Organisation | The Drake Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2016 |
End | 04/2019 |
Description | EC ERASMUS+, European University of Brain and Technology (NeurotechEU) (awarded to Kia Nobre) |
Amount | € 422,000 (EUR) |
Organisation | European Council |
Sector | Public |
Country | Belgium |
Start | 09/2020 |
End | 09/2023 |
Description | EC Horizon, European University of Brain and Technology - Research & Innovation (awarded to Kia Nobre) |
Amount | £230,000 (GBP) |
Organisation | European Commission |
Sector | Public |
Country | European Union (EU) |
Start | 03/2021 |
End | 09/2023 |
Description | ECR grant award for Bryan Ng |
Amount | £425 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2020 |
End | 03/2021 |
Description | EM7 Connectivity changes in early Alzheimer's Disease. |
Amount | £94,384 (GBP) |
Funding ID | MC_ST_CBU_2019 |
Organisation | MRC Doctoral Training Program |
Sector | Academic/University |
Country | United Kingdom |
Start | 09/2019 |
End | 09/2023 |
Description | EM7 NTAD: new-therapeutics-in-alzheimers-disease |
Amount | £1,200,000 (GBP) |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 05/2018 |
End | 09/2020 |
Description | EM7 UCB-J PET |
Amount | £370,000 (GBP) |
Organisation | Janssen Research & Development |
Sector | Private |
Country | Global |
Start | 08/2019 |
End | 06/2020 |
Description | EU IMI-2. Amyloid imaging to prevent Alzheimer's disease (AMYPAD) |
Amount | £934,500 (GBP) |
Organisation | European Social Survey: European Research Infrastructure Consortium (ESS ERIC) |
Sector | Charity/Non Profit |
Country | European Union (EU) |
Start | 09/2016 |
End | 09/2021 |
Description | Early-onset depression: Characterising development and identifying risks |
Amount | £763,680 (GBP) |
Funding ID | MR/R004609/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 11/2017 |
End | 11/2020 |
Description | Elliot Mock - Validation of USP14 as a therapeutic target in Parkinson's disease. |
Amount | £150,000 (GBP) |
Organisation | Netherlands Organisation for Scientific Research (NWO) |
Sector | Public |
Country | Netherlands |
Start | 09/2021 |
End | 09/2023 |
Description | Enhancing autophagic flux in Parkinson's disease |
Amount | $663,000 (USD) |
Organisation | Michael J Fox Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 09/2017 |
End | 09/2019 |
Description | Expanding DPUK genetics and integrating with inflammation/immunity research |
Amount | £100,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2019 |
Description | Exploration of inflammatory APOE44 astrocytic phenotypes |
Amount | £29,723 (GBP) |
Funding ID | 5245665 |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2023 |
End | 02/2024 |
Description | FENS travel award for Bryan Ng |
Amount | € 75 (EUR) |
Organisation | Federation of European Neuroscience Societies (FENS) |
Sector | Private |
Country | Belgium |
Start | 06/2020 |
End | 07/2020 |
Description | Farr NLP open source software development |
Amount | £48,470 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 11/2017 |
End | 10/2018 |
Description | Functional screening of Parkinson's GWAS loci in human iPSC neurons |
Amount | £1,400,000 (GBP) |
Organisation | GlaxoSmithKline (GSK) |
Sector | Private |
Country | Global |
Start | 12/2020 |
End | 06/2024 |
Description | GENetic Frontotemporal dementia Imaging - Second phase (GENFI-2) |
Amount | £2,613,582 (GBP) |
Funding ID | MR/M023664/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 04/2015 |
End | 04/2020 |
Description | Gates Ventures Interoperability Funding |
Amount | £612,845 (GBP) |
Organisation | Bill and Melinda Gates Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 02/2019 |
End | 04/2020 |
Description | Genetics collaboration with Prof Bart De Strooper UK DRI programme |
Amount | £50,000 (GBP) |
Organisation | UK Dementia Research Institute |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2021 |
End | 04/2022 |
Description | Genetics collaboration with Prof Bart De Strooper UK DRI programme |
Amount | £50,000 (GBP) |
Organisation | UK Dementia Research Institute |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2021 |
End | 04/2022 |
Description | HDR UK Multiomics |
Amount | £77,625 (GBP) |
Funding ID | CFC0107 |
Organisation | Health Data Research UK |
Sector | Private |
Country | United Kingdom |
Start | 03/2020 |
End | 03/2022 |
Description | HDRUK |
Amount | £3,003,650 (GBP) |
Funding ID | NIWA1 |
Organisation | Health Data Research UK |
Sector | Private |
Country | United Kingdom |
Start | 04/2018 |
End | 04/2023 |
Description | HTA grant: : A multi-centre randomised controlled trial of the clinical and cost-effectiveness of sertraline in preventing depression in adults following a traumatic brain injury (awarded to Vanessa Raymont) |
Amount | £1,988,751 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 08/2021 |
End | 08/2024 |
Description | Harnessing the power of advanced imaging for dementia diagnosis |
Amount | $137,461 (USD) |
Funding ID | AARF-21-846366 |
Organisation | Alzheimer's Association |
Sector | Charity/Non Profit |
Country | United States |
Start | 01/2022 |
End | 12/2023 |
Description | High content imaging of iPSC-derived neurons to dissect mechanisms of Parkinson's |
Amount | £80,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2017 |
End | 09/2021 |
Description | Identifying genetic biomarkers of survival for bowel cancer to aid patient management |
Amount | £90,000 (GBP) |
Organisation | Tenovus Cancer Care |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2019 |
End | 09/2022 |
Description | Improving prevention trials in AD through imaging |
Amount | £249,965 (GBP) |
Funding ID | 261 (AS-PG-15-025) |
Organisation | Alzheimer's Society |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2016 |
End | 02/2017 |
Description | Inflammation in frontotemporal lobar degeneration - from diagnosis and prognosis to clinical trials - Dr M Malpetti |
Amount | £495,687 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2022 |
End | 02/2027 |
Description | Iona Thomas Wright : Departmental Neuroscience DPhil Studentship Understanding the mechanisms of pathological alpha-synuclein cell-to-cell transfer |
Amount | £75,000 (GBP) |
Organisation | University of Oxford |
Sector | Academic/University |
Country | United Kingdom |
Start | 09/2022 |
End | 09/2026 |
Description | JPND |
Amount | £350,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 04/2016 |
End | 05/2019 |
Description | JPND EUFIND |
Amount | £30,000 (GBP) |
Organisation | EU Joint Programme - Neurodegenerative Disease Research (JPND) |
Sector | Public |
Country | European Union (EU) |
Start | 09/2016 |
End | 10/2017 |
Description | Johanna Hoffman - Understanding organellar calcium signalling in Parkinson's iPSC-dopamine neurons |
Amount | £100,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2023 |
End | 09/2026 |
Description | Kellogg College Travel Grant |
Amount | £381 (GBP) |
Organisation | University of Oxford |
Department | Kellogg College |
Sector | Academic/University |
Country | United Kingdom |
Start | 11/2022 |
End | 04/2023 |
Description | Leveraging human genetics to identify target populations for dementia therapeutics (Eisai/DRI), project grant |
Amount | £200,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2020 |
End | 02/2023 |
Description | MIND-MAPS |
Amount | £977,920 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2017 |
End | 03/2020 |
Description | MJ Fox Therapeutic Pipeline Program: Enhancing autophagy flux in Parkinson's disease |
Amount | $330,000 (USD) |
Organisation | Michael J Fox Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start |
Description | MR/T033371/1 - DPUK2 Integrated Dementia Experimental Medicine |
Amount | £7,670,000 (GBP) |
Funding ID | MR/T033371/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2021 |
End | 12/2025 |
Description | MRC CASE Award with Biogen (Principal Supervisor to William McGuiness. Molecular mechanisms of TFEB in Parkinson's |
Amount | £200,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2019 |
End | 09/2022 |
Description | MRC COEN |
Amount | £150,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 05/2016 |
End | 06/2018 |
Description | MRC Momentum Award (Microglial interactions in Alzheimer's Disease) |
Amount | £4,300,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2017 |
Description | MRC Momentum Award (Microglial interactions in Alzheimer's Disease-informatics) |
Amount | £1,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | MRC Partnership Award (Dementias Platform UK Stem Cell Partnership) |
Amount | £1,200,000 (GBP) |
Funding ID | MR/N013255/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 06/2016 |
End | 06/2020 |
Description | MRC Partnership grant for UK7T |
Amount | £220,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2016 |
End | 03/2019 |
Description | MRC Project Grant MR/V013599: Identifying the regulation of striatal dopamine function by striatal astrocytes in health and parkinsonism (Prof S Cragg & Prof R Wade-Martins) |
Amount | £1,038,078 (GBP) |
Funding ID | MR/V013599 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 02/2021 |
End | 01/2024 |
Description | MRC UK Dementia Research Institute Award - Dementia Bench to Bedside |
Amount | £6,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2017 |
End | 10/2022 |
Description | MRC World Class Labs Capital Funding 2023/24 |
Amount | £54,000 (GBP) |
Funding ID | 526618 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 12/2023 |
End | 03/2024 |
Description | MRC-KHIDI UK-KOREA PARTNERING AWARDS |
Amount | £100,000 (GBP) |
Funding ID | MC_PC_18006 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2017 |
End | 04/2018 |
Description | MRC-NIH UK-US Dementia Research Collaboration programme |
Amount | £11,000 (GBP) |
Funding ID | MC_PC_17204 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2019 |
Description | Mapping the Modulatory Landscape Governing Striatal Dopamine Signaling and Its Dysregulation in Parkinson's Disease. |
Amount | $9,000,000 (USD) |
Organisation | Aligning Sciences Across Parkinson's |
Sector | Charity/Non Profit |
Country | United States |
Start | 11/2021 |
End | 10/2024 |
Description | Maria Claudia Caiazza was awarded an ARUK Thames Valley network Pilot Award |
Amount | £2,500 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2021 |
End | 06/2021 |
Description | Mental Health Pathfinder Award |
Amount | £1,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | Michael J Fox Foundation: In depth phenotypic profiling of PINK1/Parkin stem cell-derived neurons and glia.(Prof Wade-Martins) |
Amount | $600,000 (USD) |
Organisation | Michael J Fox Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 08/2021 |
End | 02/2023 |
Description | Michael J Fox Foundation: Transcriptomic changes in iPSC-derived dopaminergic neurons induced by exposure to alpha-synuclein revealed by single cell RNA-Seq. |
Amount | $200,000 (USD) |
Organisation | Michael J Fox Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 03/2021 |
End | 09/2022 |
Description | Michael J Fox Foundation: Validation of FASN as a target for therapeutic development in PD.(Prof Wade-Martins) |
Amount | $200,000 (USD) |
Organisation | Michael J Fox Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 03/2021 |
End | 11/2022 |
Description | Mootaz Salman - Organ-on-a-chip human patient stem cell models of the blood-barrier in Parkinson's disease. |
Amount | £115,000 (GBP) |
Organisation | The Leverhulme Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2022 |
End | 04/2025 |
Description | NIHR Development and Skills Enhancement Award - Ivan |
Amount | £34,333 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 02/2021 |
End | 02/2022 |
Description | Natalie Connor-Robson Lockey Fund- for travel to World Parkinson's congress |
Amount | £500 (GBP) |
Organisation | Lockey Committee |
Sector | Academic/University |
Country | United Kingdom |
Start | 05/2019 |
Description | Natural Sciences and Engineering Research Council of Canada DPhil Scholarship, and Clarendon Award (Co-supervisors to Kaitlyn Cramb Prof. Richard Wade-Martins & Prof Stephanie Cragg ). In vitro iPSC-derived neuronal circuit models of Parkinson's |
Amount | £117,000 (GBP) |
Organisation | Natural Sciences and Engineering Research Council of Canada (NSERC) |
Sector | Public |
Country | Canada |
Start | 09/2019 |
End | 09/2022 |
Description | New Therapeutics in Alzheimer s Disease (NTAD) - ARUK |
Amount | £100,000 (GBP) |
Funding ID | RG89702 |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2017 |
End | 08/2020 |
Description | Oxford Biomedical Research Centre (BRC) |
Amount | £45,000 (GBP) |
Organisation | National Institute for Health Research |
Department | NIHR Biomedical Research Centre |
Sector | Public |
Country | United Kingdom |
Start |
Description | Oxford Medical Sciences Divisions Returning Carer Fund (Tara Caffrey) |
Amount | £5,000 (GBP) |
Organisation | University of Oxford |
Sector | Academic/University |
Country | United Kingdom |
Start | 02/2017 |
End | 05/2017 |
Description | Peter Kilfeather awarded funding to study using spatial transcriptomics to look at SNpc and VTA gene expression on wild-type mice compared to SNCA-OVX mice. |
Amount | £22,151 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 05/2021 |
End | 12/2021 |
Description | Pilot study to develop an instrument to capture broad-ranging neurodevelopmental problems in children with a genetic diagnosis of intellectual disability |
Amount | £48,502 (GBP) |
Organisation | Baily Thomas Charitable Fund |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2019 |
End | 10/2020 |
Description | Pilot study to develop an instrument to capture broad-ranging neurodevelopmental problems in children with a genetic diagnosis of intellectual disability |
Amount | £48,502 (GBP) |
Organisation | Baily Thomas Charitable Fund |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2019 |
End | 10/2020 |
Description | Polygenic risk scores for neurodegeneration and Alzheimer's pathophysiology |
Amount | £951 (GBP) |
Organisation | UK Dementia Research Institute |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2020 |
End | 11/2021 |
Description | Post-COVID cognitive impairment: characterisation and intervention |
Amount | £380,000 (GBP) |
Organisation | MQ Mental Health Research |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2022 |
End | 11/2022 |
Description | Post-Doctoral Fellowship (Supervisor to Dr Charmaine Lang): (£210,000; 01/10/19-30/09/21) New molecular targets in Parkinson's disease. |
Amount | £210,000 (GBP) |
Organisation | AstraZeneca |
Sector | Private |
Country | United Kingdom |
Start | 09/2019 |
End | 09/2021 |
Description | Predicting dementia outcomes using simple, non-invasive assessments: a prospective population-based study |
Amount | £207,016 (GBP) |
Funding ID | MR/P001823/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 07/2016 |
End | 07/2019 |
Description | Profiling post-translational modifications of histone proteins as a determinant of Parkinson's susceptibility |
Amount | £232,404 (GBP) |
Funding ID | G-1502 |
Organisation | Parkinson's UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2016 |
End | 07/2018 |
Description | Progressive Supranuclear Palsy Association Small Research Grant |
Amount | £9,279 (GBP) |
Organisation | Progressive Supranuclear Palsy Association (PSPA) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2022 |
Description | Proinflammatory cytokines as Parkinson's biomarkers |
Amount | $184,247 (USD) |
Organisation | Michael J Fox Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 06/2023 |
End | 12/2024 |
Description | Race Against Dementia Project Expansion Funds- Dr M Malpetti |
Amount | £500,000 (GBP) |
Organisation | Race Against Dementia |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2023 |
Description | Rachel Heon-Roberts, Clarendon Fund & Dept of Physiology, Anatomy, & Genetics. Project title: Establishing a model of a-synuclein and amyloid-ß-induced mitochondrial & lysosomal dysfunction in Alzheimer's disease, PD & Lewy Body dementias |
Amount | £105,000 (GBP) |
Organisation | University of Oxford |
Sector | Academic/University |
Country | United Kingdom |
Start | 09/2021 |
End | 09/2024 |
Description | Restoring noradrenergic function to improve apathy in Parkinson s disease to Claire O Callaghan |
Amount | £49,677 (GBP) |
Funding ID | RG90797 |
Organisation | Parkinson's UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2017 |
End | 07/2018 |
Description | Rosetrees: Detecting and tracking brain changes in early Alzheimer's Disease |
Amount | £248,130 (GBP) |
Funding ID | M668-CD1 |
Organisation | Rosetrees Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2017 |
End | 08/2020 |
Description | SAIL Dementia eCohort |
Amount | £50,308 (GBP) |
Organisation | UK Dementia Research Institute |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2021 |
End | 08/2021 |
Description | SRUK winter studentship |
Amount | € 2,400 (EUR) |
Organisation | Society of Spanish Researchers in the United Kingdom |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Sanofi/Genzyme: Modulating GBA activity as a Parkinson's disease therapy |
Amount | £200,000 (GBP) |
Organisation | Sanofi |
Department | Genzyme Therapeutics Ltd |
Sector | Private |
Country | United Kingdom |
Start | 11/2016 |
End | 10/2017 |
Description | Senior Research Leaders Discretionary Award |
Amount | £15,000 (GBP) |
Organisation | Health and Care Research Wales |
Sector | Public |
Country | United Kingdom |
Start | 03/2021 |
End | 03/2022 |
Description | Senior Research Leaders Discretionary Award |
Amount | £60,000 (GBP) |
Funding ID | SRL2022-25-09 |
Organisation | Health and Care Research Wales |
Sector | Public |
Country | United Kingdom |
Start | 03/2022 |
End | 03/2023 |
Description | Stefania Guisanni was successful with an ARUK ECR video awards |
Amount | £320 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2021 |
End | 12/2021 |
Description | Stratification of bipolar disorder: Harnessing clinical heterogeneity and genetics shared with other disorders |
Amount | £310,234 (GBP) |
Funding ID | Judith Allardyce |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2018 |
End | 12/2021 |
Description | Stratification of bipolar disorder: Harnessing clinical heterogeneity and genetics shared with other disorders |
Amount | £310,234 (GBP) |
Funding ID | 209176 |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2018 |
End | 06/2022 |
Description | TRanslating Individual Alzheimer GEnetic risk into disease phenotypes [TRIAGE] |
Amount | € 420,000 (EUR) |
Organisation | JPND Research |
Sector | Academic/University |
Country | Global |
Start | 04/2020 |
End | 04/2023 |
Description | Targeting HDAC4 in Parkinson's disease |
Amount | £50,000 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2020 |
End | 02/2021 |
Description | Targeting disease phenotypes in Parkinson's patient iPSC-derived dopamine neurons |
Amount | £650,000 (GBP) |
Organisation | GlaxoSmithKline (GSK) |
Sector | Private |
Country | Global |
Start | 09/2020 |
End | 09/2022 |
Description | The Airwave Health Monitoring Study (AHMS). An Occupational Cohort Study of the British Police Forces |
Amount | £1,941,097 (GBP) |
Funding ID | MR/R023484/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 04/2018 |
End | 04/2023 |
Description | The Moondance Dementia Research Laboratory |
Amount | £5,000,000 (GBP) |
Funding ID | 525036 |
Organisation | The Moondance Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2023 |
End | 08/2028 |
Description | The UKDRI IPSC Platform to Model Alzheimer's Disease Risk (IPMAR). SA Cowley |
Amount | £1,770,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2021 |
End | 12/2023 |
Description | The development and implementation of polygenic risk algorithms for stratifying individuals for future cognitive decline due to Alzheimer's disease in non-symptomatic and early cognitive impaired subjects |
Amount | £288,555 (GBP) |
Funding ID | 104210 |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 02/2020 |
Description | The impact of AD-associated risk variants in complement genes on neurodegeneration |
Amount | £271,303 (GBP) |
Funding ID | 523088 |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2023 |
End | 09/2026 |
Description | The physiology of dementia: magnetoencephalographic investigation of brain networks in frontotemporal lobar degeneration and Alzheimer's disease in preparation for experimental medicine studies. |
Amount | £49,592 (GBP) |
Funding ID | RG84879 |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2016 |
End | 09/2017 |
Description | Transcriptomic changes in iPSC-derived dopaminergic neurons induced by exposure to alpha-synuclein revealed by single cell RNA-Seq. |
Amount | $200,000 (USD) |
Organisation | Michael J Fox Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 06/2021 |
End | 02/2023 |
Description | Transcriptomic changes in iPSC-derived dopaminergic neurons induced by exposure to alpha-synuclein revealed by single cell RNA-Seq. |
Amount | $200,000 (USD) |
Organisation | Michael J Fox Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 08/2021 |
End | 02/2023 |
Description | Travel grant for conference for Bryan Ng |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2020 |
End | 03/2020 |
Description | Travel grant for conference for Bryan Ng |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2020 |
End | 03/2020 |
Description | Travel grant for conference for Bryan Ng |
Amount | £300 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2019 |
End | 03/2019 |
Description | UKDRI Core Budget - Project 1 |
Amount | £1,686,147 (GBP) |
Funding ID | 524209 |
Organisation | UK Dementia Research Institute |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2023 |
End | 03/2028 |
Description | UKDRI Core Budget - Project 2 |
Amount | £1,547,766 (GBP) |
Funding ID | 524210 |
Organisation | UK Dementia Research Institute |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2023 |
End | 03/2024 |
Description | UKRI Innovation / Rutherford Fund Fellowships at HDR UK |
Amount | £560,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 02/2018 |
End | 02/2021 |
Description | Understanding vulnerability and resistance in Alzheimer's disease |
Amount | £99,428 (GBP) |
Organisation | Janssen Biotech, Inc. |
Sector | Private |
Country | United States |
Start | 03/2023 |
End | 03/2024 |
Description | Uniting iPSCS and CRISPR/Cas9 screens- a platform to model and interrogate genetic disease in Oxford |
Amount | £80,000 (GBP) |
Organisation | University of Edinburgh |
Department | Institutional Strategic Support Fund |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 12/2017 |
End | 06/2019 |
Description | University of Cambridge/Montreal Neurological Institute-Hospital Neuroscience Collaboration - Dr M Malpetti (Rowe Group) |
Amount | $50,000 (CAD) |
Organisation | University of Montreal |
Department | Montreal Neurological Institute |
Sector | Hospitals |
Country | Canada |
Start | 11/2023 |
End | 02/2025 |
Description | Validating prognostic biomarkers for colorectal cancer and determining their clinical utility |
Amount | £155,801 (GBP) |
Organisation | Cancer Research Wales |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2018 |
End | 10/2021 |
Description | WP7 ARUK Pilot Award: "Disentangling contributions of the hippocampus and striatum in efficient memory-guided attention" |
Amount | £3,990 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2020 |
End | 08/2020 |
Description | WP7 EU Innovative Training Network: European School of Network Neuroscience (awarded to Kia Nobre & Mark Woolrich) |
Amount | € 3,966,875 (EUR) |
Organisation | European Commission |
Sector | Public |
Country | European Union (EU) |
Start | 09/2019 |
End | 10/2023 |
Description | WP7 German Research Foundation Fellowship to Dr Anna-Katharina Bauer (supervisor Kia Nobre) |
Amount | € 60,000 (EUR) |
Organisation | German Research Foundation |
Sector | Charity/Non Profit |
Country | Germany |
Start | 08/2019 |
End | 08/2021 |
Description | WP7 Marie Sklodowska-Curie Postdoctoral Fellowship to Dr Méadhbh Brosnan (supervisor Kia Nobre) |
Amount | € 212,934 (EUR) |
Organisation | European Commission |
Sector | Public |
Country | European Union (EU) |
Start | 08/2019 |
End | 08/2021 |
Description | WP7 Oxford-Berlin Collaboration: "Dynamics of memory systems in the brain" (awarded to Kia Nobre) |
Amount | € 25,000 (EUR) |
Organisation | University of Oxford |
Department | Oxford–Berlin Research Partnership |
Sector | Academic/University |
Country | United Kingdom |
Start | 01/2020 |
End | 12/2020 |
Description | WP7 Royal Society Newton Advanced Fellowships and Mobility Grants to Dr André Cravo |
Amount | £60,000 (GBP) |
Organisation | The Royal Society |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2019 |
End | 08/2021 |
Description | Wales/NI substantive site. HDR UK |
Amount | £3,003,650 (GBP) |
Organisation | Health Data Research UK |
Sector | Private |
Country | United Kingdom |
Start | 04/2018 |
End | 04/2023 |
Description | Wellcome Centre for Integrative Neuroimaging - extension |
Amount | £3,101,188 (GBP) |
Funding ID | 203139/A/16/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2022 |
End | 04/2025 |
Description | Wellcome Integrative Neuroimaging Seed funding - £12,000 . Natalie Connor-Robson |
Amount | £12,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Wellcome Trust Clinical Research Training Fellowship |
Amount | £174,791 (GBP) |
Organisation | Wellcome Trust |
Department | Wellcome Trust Bloomsbury Centre |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2016 |
End | 03/2019 |
Description | Wellcome Trust Clinical Training Fellowship |
Amount | £174,791 (GBP) |
Organisation | Wellcome Trust |
Department | Wellcome Trust Bloomsbury Centre |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2016 |
End | 03/2019 |
Description | Wellcome Trust DPhil Studentship in Neuroscience: Characterisation of a novel GBA-L444P BAC transgenic mouse model of Parkinson's. (Supervisor to Tara Diviney, Co-Supervisor Prof Stephanie Cragg |
Amount | £104,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2020 |
End | 09/2023 |
Description | Weston Brain Institute - Developing blood based biomarkers to detect pre-clinical Alzheimer's disease and predict progression |
Amount | £329,663 (GBP) |
Organisation | Weston Brain Institute |
Sector | Private |
Country | Canada |
Start | 12/2020 |
End | 12/2020 |
Description | Weston Brain Institute - Developing blood based biomarkers to detect preclinical Alzheimer's disease and predict progression |
Amount | £329,663 (GBP) |
Organisation | Weston Brain Institute |
Sector | Private |
Country | Canada |
Start | 01/2018 |
End | 10/2020 |
Description | What makes strategic stroke strategic? Multimodal imaging and network methods to predict dementia after strategic stroke |
Amount | £4,000 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2017 |
End | 08/2017 |
Description | Wolfson Foundation: Ageing Cohort |
Amount | £887,193 (GBP) |
Organisation | The Wolfson Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2013 |
End | 03/2019 |
Title | Alzheimer's Disease Data Intiative (ADDI) Workbench |
Description | Development of a proof of concept system for international data platform data sharing and collaboration. The tool is available to other members of the international working group.. |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2020 |
Provided To Others? | Yes |
Impact | Development of technology solutions for data cataloguing, data identification and federated computation that can facilitate greater cross-platform data access and therefore scientific developments. |
Title | BIOFIND output |
Description | The JPND BioIND project was led from MRC-CBU, as an international collaboration to standardize and harmonize methods for dementia research. |
Type Of Material | Physiological assessment or outcome measure |
Year Produced | 2019 |
Provided To Others? | Yes |
Impact | Data sharing across sites, the open science methods and a publication pending are outputs related to the validation and recommendations made. The research tool is part of the growing recognition of MEG's potential to transform dementia research, with novel mechanistic insights and trials outcomes, provided that industry-readiness benchmarks can be met. |
URL | http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/closed-calls/brain-im... |
Title | CRISPR gene editing |
Description | We have been able to establish CRISPR/Cas9 gene editing in our lab as a result of this project |
Type Of Material | Technology assay or reagent |
Year Produced | 2015 |
Provided To Others? | Yes |
Impact | We have been able to perform gene editing in iPSC lines. |
Title | DPUK Data Portal |
Description | The DPUK Data Portal has been relaunched to include a seamless transition from the DPUK main welcome site into the research infrastructure. The Portal, hosted by Swansea University, now includes openly available metadata on the DPUK cohorts, as well as information on the various parts of the infrastructure, which include: Portal analysis environment powered by virtual desktop infrastructure, imaging platform powered by XNAT, genetic platform created by Digital Health Labs, data linkage possibilities using world-leading matching technology, and a new and easy-to-use application form for researchers to apply for access to data, based on categorised dementia-specific data ontologies. The Portal is now supporting data access applications with dedicated resource to manage this process, and data management based on consultation with other data consortia and the cohorts themselves is underway using novel data management infrastructure (research data appliance based at Swansea University), enabling governance to remain entirely with the data provider and data access permissions to be managed by a central facility. |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2017 |
Provided To Others? | Yes |
Impact | The relaunch of the Portal has seen a surge in scientific collaboration in DPUK - for the period November 2017-January 2018, there are 12 live studies on the Portal, all using multiple cohorts and all cross-institution, including internationally-led studies from Maastricht University and the University of Hong Kong. These studies have primarily phenotypic data as their main modality, however we are also seeing the combination of phenotypic, genotypic and imaging data in studies, thus showing the power of a central system for accessing and analysing data from previously disparate sources. Genetics and imaging work packages are also contributing to the studies being supported by DPUK, and the Portal is making data available to specialists in these areas in order for them to derive services for the epidemiological community to make use of data that was previously unobtainable, either due to access difficulties or specialist intervention being necessary. |
URL | https://portal.dementiasplatform.uk/ |
Title | DPUK Data Portal Datathon Virtual Desktop |
Description | Bespoke virtual desktop infrastructure for DPUK Datathons - comprising of dedicated 32GB RAM/4 CPU machines supporting up to 60 concurrent users. Pre-loaded with software such as Stata 16, SPSS, SAS, R, Python (Anaconda), PyCharm, Spyder, Jupyter Notebook, Eclipse, SQL Server Management Studio, Matlab, and Office. |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2018 |
Provided To Others? | Yes |
Impact | The dedicated Datathon desktop has allowed us to run 4 DPUK Datathon events across the UK, which have had an international audience of over 150 researchers cumulatively. |
URL | https://portal.dementiasplatform.uk/ |
Title | DPUK Imaging Network- Harmonising of Imaging protocols |
Description | One important aspect of the work of the DPUK Imaging Network is the harmonising and optimising of protocols for image data acquisition, reconstruction, and analysis. This is currently in progress. There is a dedicated website for the MR/PET Partnership, a sub-group within the Imaging Network. The harmonised protocols will appear here once available: https://www.dpuk-mripet.info/ |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2018 |
Provided To Others? | Yes |
Impact | Complete harmonisation has yet to be achieved but this should happen in the first half of 2019. |
Title | DPUK Stem Cell Network iPSC directory resource for researchers |
Description | Members of the DPUK Stem Cell Network have produced a directory listing over 100 iPSC lines that could be made available to researchers in collaboration with the labs who generated the lines. The directory can be found on the DPUK website. It is available via the DPUK website and contact being made with the lead researcher who generated the lines. |
Type Of Material | Cell line |
Year Produced | 2018 |
Provided To Others? | Yes |
Impact | The Stem Cell Network has published a range of papers using the resource. For an illustrative example please see a recent 2019 paper from the laboratory of Professor Richard Wade- Martins, the lead of the Stem Cell Network. https://academic.oup.com/hmg/advance-article/doi/10.1093/hmg/ddz038/5315478 |
URL | https://www.dementiasplatform.uk/for-researchers/expert-communities-1/stem-cells-network-1/ipsc-reso... |
Title | Dementia Diagnosis Algorithm for use in primary care, hospital admissions or mortality datasets |
Description | The researchers from DPUK WP9 used data from ~17,000 UK Biobank participants to identify participants with one or more dementia codes in primary care, hospital admissions or mortality datasets, and compared the coded data to the full-text medical record. Having validated the accuracy of these datasets, they then developed algorithms that can be applied to identify participants with dementia in UK Biobank and other DPUK cohorts. The authors will continue this promising work by investigating sources of potential bias in the data and the generalisability of these findings to older ages and other geographical areas. |
Type Of Material | Model of mechanisms or symptoms - human |
Year Produced | 2019 |
Provided To Others? | Yes |
Impact | This is an initial validation study which has proved that the methodology works. Following recent publication of the results (March 2019) the work will be expanded and the findings built-on. |
Title | Dementias Platform UK: Cognitive Test Directory. |
Description | Dementias Platform UK: Cognitive Test Directory. Oxford, UK: DPUK; 2019. for use on the DPUK Data Portal |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2019 |
Provided To Others? | Yes |
Impact | Calvin C, et al. Dementias Platform UK: Cognitive Test Directory. Oxford, UK: DPUK; 2019. Downloadable from: https://www.dementiasplatform.uk/for researchers/get-ahead-with-cognitive-test-data-1/cognitive-test-directory |
URL | https://www.dementiasplatform.uk/for%20researchers/get-ahead-with-cognitive-test-data-1/cognitive-te... |
Title | Development of an enhanced Cognitive Assessment for UK Biobank |
Description | A DPUK funded group (WP10) led by Ian Deary in Edinburgh are working closely with UK Biobank to develop an enhanced cognitive assessment, including tests of cognitive function known to be sensitive to ageing. This includes more detailed tests of declarative memory, reasoning and executive function. There are some limitations of the scope for the tests; a brief period of time is allowed for testing to fit with any planned clinical visits for UK Biobank participants and it has to be self-administered on a computer touch screen. The group has produced a report for UK Biobank on the enhanced UK Biobank cognitive assessment and provided their preliminary assessment of the test characteristics. Subject to UK Biobank approval, it is hoped to provide details of the tests on the DPUK website. Preliminary report to UK Biobank is dated 21.09.2017 and is in the process of being updated. |
Type Of Material | Model of mechanisms or symptoms - human |
Year Produced | 2017 |
Provided To Others? | Yes |
Impact | There has been a revision of the tests administered in UK Biobank and an improvement in their quality. This means that they are now more informative for investigating the variety and subtlety of cognitive changes seem in both healthy and pathological ageing. |
Title | Dopamine neuron microfluidics |
Description | Development of stem cell-derived neuronal culture techniques using microfluidic devices to channel axonal growth. |
Type Of Material | Model of mechanisms or symptoms - in vitro |
Provided To Others? | No |
Impact | Not yet: it is ongoing development |
Title | Generation of MAPT CRISPR gene edited iPSC lines |
Description | We have generated 8 QCed MAPT-/- knockout lines on 2 control backgrounds. |
Type Of Material | Cell line |
Year Produced | 2018 |
Provided To Others? | No |
Impact | We will use the MAPT-/- iPSC-derived neurons to study the role of MAPT in Parkinson's |
Title | Generation of SNCA CRISPR gene edited iPSC lines |
Description | We have generated 3 QCed SNCA-/- knockout lines on control background and isogenic correction of SNCA Triplication patient line (and also knockout) - clones identified by droplet digital PCR, undergoing confirmatory sequencing. |
Type Of Material | Cell line |
Year Produced | 2018 |
Provided To Others? | No |
Impact | Generation of SNCA CRISPR gene edited lines will further our work on the role of macrophages and microglia on the uptake/processing/secretion of alpha-synuclein and its role in stimulating the immune response and enable us to interrogate the mechanism for the phagocytosis defect phenotype observed in the SNCA-Triplication macrophages/microglia. |
Title | High content, high throughput analysis |
Description | The ability to perform detailed high-throughput analysis of neurons in culture |
Type Of Material | Technology assay or reagent |
Year Produced | 2016 |
Provided To Others? | Yes |
Impact | Shared use of best practice in high-throughput analysis using Opera Phenix imager and high-throughout plate readers |
Title | In vitro electrophysiology |
Description | Patch-clamp techniques to measure neuronal activity of stem cell-derived neurons |
Type Of Material | Technology assay or reagent |
Provided To Others? | No |
Impact | Analaysis of stem cell-derived neurons: dopamine neurons, cortical neurons, motor neurons and medium spiny neurons |
Title | Live cell imaging techniques in iPS-derived DA neurons in vitro |
Description | We have optimised a live cell imaging protocol for the visualisation and measurement of mitochondrial membrane potential in differentiated neurons. |
Type Of Material | Cell line |
Provided To Others? | No |
Impact | The membrane potential-sensing dye TMRM can be used to quantify membrane potential, with increased fluorescence indicating increased membrane potential. |
Title | Microglia differentiation |
Description | The ability to generate microglia from human stem cells from dementia patients |
Type Of Material | Cell line |
Provided To Others? | No |
Impact | We will be able to compare the function of microglia generated from patients and from controls |
Title | PLA in stem cell neurons |
Description | To enable the detection of a-syn oligomers in stem cell-derived dopamine neurons |
Type Of Material | Technology assay or reagent |
Year Produced | 2017 |
Provided To Others? | Yes |
Impact | The detection of a-syn oligomers in stem cell-derived dopamine neurons |
Title | Pipelines for processing MR data |
Description | Novel pipelines for processing MR data (in conjunction with DPUK imaging platform) |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2016 |
Provided To Others? | Yes |
Impact | Establish pipelines to process MR data and combine that data in an imaging platform used by other DPUK cohorts |
Title | Pipelines for processing PET data from PET/MR |
Description | Creation of novel pipelines for processing PET data from PET/MR |
Type Of Material | Improvements to research infrastructure |
Provided To Others? | No |
Impact | These pipelines allow for improved efficiency and accuracy in the processing of PET data that is received from a PET/MR scanner. |
Title | RNA-Seq |
Description | Development of methods for analysis of RNA-Seq |
Type Of Material | Technology assay or reagent |
Provided To Others? | No |
Impact | Understanding of gene expression profiles in selected cell population |
Title | Target discovery assays |
Description | Develop target discovery assays using high throughput screens |
Type Of Material | Technology assay or reagent |
Provided To Others? | No |
Impact | New research facilty built for our work |
Title | iPSC phenotypic screens |
Description | We have developed an organelle calcium flux assay for high-throughput screening and applied the assay to screen 4000 small molecules in Parkinson's patient iPSC-dervied dopamine neurons. |
Type Of Material | Technology assay or reagent |
Year Produced | 2018 |
Provided To Others? | No |
Impact | We will use the assay to identify new therapeutic targets or novel and or repurposable small molecule therapeutics. |
Title | Alzhemer's Disease Polygenic Risk Profiling |
Description | This model used data from the powerful dataset comprising 17 008 cases and 37 154 controls obtained from the International Genomics of Alzheimer's Project (IGAP). Alzheimer's disease (AD) Polygenic risk scores were generated for 3177 cases and 7277 controls (GERAD data) and tested whether the alleles identified to associate with disease in IGAP sample are significantly enriched in the cases relative to the controls in the GERAD sample. The disease prediction accuracy was investigated in a sample of 3049 cases and 1554 controls (for whom APOE genotype data was available) by means of sensitivity, specificity, area under the receiver operating characteristic curve (AUC) and positive and negative predictive values. The best prediction accuracy AUC = 78.2% (95% confidence interval 77-80%) was achieved by a logistic regression model with APOE, the polygenic score, sex and age as predictors. |
Type Of Material | Computer model/algorithm |
Year Produced | 2016 |
Provided To Others? | Yes |
Impact | This approach is used to create SNP arrays for AD prediction (for research only so far). |
Title | C-Surv Ontology |
Description | The C-Surv ontology was finalised for the curation of DPUK Cohort Data. The onotology is comprised of 20 top-level and 140 2nd-level categories and all cohort data are categoried according to these. Standardisation of naming structure is an ongoing programme across all cohorts. Also, harmonisation of a 30-variable minimal dementia-focused dataset and updating of the DPUK Data Portal metadata tools, according to the C-Surv ontology. |
Type Of Material | Data handling & control |
Year Produced | 2019 |
Provided To Others? | No |
Impact | Paper has been written, awaiting submission. The model may be adopted by cohorts and other interested parties as the standard for cohort data curation. |
Title | Cam-CAN |
Description | Cam-CAN project extended to include subarm of "Cam-CAn Frail" and early dementia participants. |
Type Of Material | Database/Collection of data |
Year Produced | 2016 |
Provided To Others? | Yes |
Impact | Extensive applications for data from CC700; Cam-CAN-Frail still in data acquisition phase. |
Title | Cerebrovascular Diseases Image Databank |
Description | Cerebrovascular Diseases Image Databank contains brain magnetic resonance & computed tomographic imaging data from patients with cerebrovascular diseases, created by Professor Joanna Wardlaw. |
Type Of Material | Database/Collection of data |
Year Produced | 2020 |
Provided To Others? | Yes |
Impact | Publicly accessible data-bank, improving research results across study groups focused on developing prevention and treatment methods for small vessel diseases, stroke and Alzheimer's disease. |
URL | https://www.ed.ac.uk/clinical-sciences/edinburgh-imaging/research/themes-and-topics/analysis-and-pro... |
Title | Clinical Studies Register |
Description | The Clinical Studies Register is an opt-out database. DPUK manages this database of willing AIRWAVE cohort participants for re-contact in clinical trials. |
Type Of Material | Database/Collection of data |
Year Produced | 2019 |
Provided To Others? | Yes |
Impact | The Clinical Studies Register holds approximately 50,000 participant records. The success and learnings of the Clinical Studies Register lead to the development of Great Minds, an opt-in register for participants who are willing to undergo deeper and more frequent geno- and phenotyping to add to their cohort records. |
URL | https://www.dementiasplatform.uk/our-impact/trails-readiness |
Title | DPUK 7T data sharing |
Description | Agreement on data sharing for 7T images using DPUK XNAT platform |
Type Of Material | Database/Collection of data |
Year Produced | 2016 |
Provided To Others? | Yes |
Impact | pending |
Title | DPUK Genomics portal |
Description | The DPUK Genetics portal provides a collaborative platform for individuals, DPUK cohorts and the wider research community to share and access research outputs from genetic research. The platform provides two key tools for finding, sharing and analysing genetic data; The Results Registry tool, accessible via the main DPUK web portal, allows searching and uploading of genetic results data. This tool provides a rich set of search tools specific to genetic data and includes visualisation using the popular JBrowse genomic browser. This tool will allow users to share this data. This can be done under secure data transfer agreements if necessary. The second tool is the Genetic Data Browser this is available exclusively within the secure DPUK infrastructure. This will allow users to create cross-cohort comparison studies based on genotypic datasets and linked phenotypic data. This tool provides an interactive dashboard which can pull in phenotypic data and genetic markers from GWAS data and allow users to intuitively explore, combine and export patient cohorts. |
Type Of Material | Database/Collection of data |
Year Produced | 2017 |
Provided To Others? | Yes |
Impact | The DPUK Genetics portal, housed on the DPUK platform, allows non bioinformatic-expert users to explore components of genetic data within a secure environment. We have provided access to an international consortium, GERAD, via the DPUK data portal. This is a dataset of over 18,000 cases and controls (detailed in Table 2), as well as over 5,600 samples to date submitted to the EADB, the European AD DNA bank for deciphering the missing heritability of Alzheimer's disease |
URL | https://portal.dementiasplatform.uk/ |
Title | DPUK Imaging Platform |
Description | Brain scan data from the imaging centres across the UK are brought together in the DPUK imaging platform - a database for anonymised brain scans from the cohort studies. |
Type Of Material | Database/Collection of data |
Year Produced | 2019 |
Provided To Others? | Yes |
Impact | The DPUK Central XNAT instance allows users to upload, manage and then share their imaging data with the Imaging Hub. The Imaging Hub allows researchers to identify cohorts of images that they wish to access, coordinate the access procedure, and create projects containing approved data for review and analysis. |
Title | DPUK Re-imaging MRI Database |
Description | The database contains MRI scans of brain and body together with self-reported health data from computerised questionnaires. The information follows the latest standard protocol in the UK Biobank imaging sub-study. This database relates to Work Package 3 of the DPUK award, relating to the re-imaging project with UK Biobank. |
Type Of Material | Database/Collection of data |
Year Produced | 2019 |
Provided To Others? | No |
Impact | The collection of data is ongoing with a target of re-imaging 10,000 subjects from the 100,000 UK Biobank participants in their imaging subs-study. This data collection is was financially (partially) supported from the DPUK award and the protocol to establish the repeat imaging protocol were developed by the DPUK research team. The major impact will come when the full dataset is complete and available to DPUK collaborators for analysis and planning of dementia related trials. The main indirect impact is that UK Biobank are now seeking philanthropic funding to extend on this project and increase repeat imaging numbers to ~70,000. These impacts were made possible by the initial imaging fund awarded to Newcastle, which leveraged a further £8M award from the MRC to UKB for whole repeat body imaging. |
Title | Early Adversity and Dementia Programme |
Description | This is a DPUK research programme for investigating the impact of early adversity on longitudinal cognitive decline and dementia. Lead by Dr Sarah Bauemeister, a team of 4 analysts work on different statistical and machine-learning models, across multiple cohorts and multi-modal data to investigate this topic. |
Type Of Material | Computer model/algorithm |
Year Produced | 2018 |
Provided To Others? | No |
Impact | One paper submitted to BioRxiv https://www.biorxiv.org/content/10.1101/749077v1 and four pending papers in progress. A DPUK Discovery award and an MRC UK-Korea award were awarded for this programme, and Gates Ventures are funding its continuation through the ADDI interoperability project (scientific use-case). |
Title | Great Minds |
Description | An opt-in database of over 2000 participants from UK-based cohorts who are willing to participate in clinical trials and enhance their phenotyping through eg CANTAB online cognitive tests and Mezurio game as a phone application. Some of these may also under genotyping for greater depth of detail. |
Type Of Material | Database/Collection of data |
Year Produced | 2019 |
Provided To Others? | No |
Impact | A potential phenotypically rich register of pre-symptomatic healthy people with existing cohort data who are ready to engage with experimental studies to help understanding of dementia. Over three-quarters have engaged with regular online cognitive testing. |
URL | https://www.greatmindsfordementia.uk/ |
Title | Great Minds CRM recontact platform connects studies with volunteers with specific characteristics |
Description | The Great Minds CRM platform is the system by which pseudo-anonymised Great Minds registry data is connected to contact and preference information and allows research assistants to invite identified volunteers with approved studies. |
Type Of Material | Data handling & control |
Year Produced | 2020 |
Provided To Others? | No |
Impact | The pilot stage has allowed research assistants to securely match a study with volunteers with specific characteristics and manage oversee the engagement - whether the participant agree to join, whether the study claimed the volunteer, whether the study is complete etc. |
Title | Insight46 XNAT database |
Description | A bespoke database has been designed for the collection of Insight46 data that is run on the XNAT platform. |
Type Of Material | Database/Collection of data |
Provided To Others? | No |
Impact | This bespoke database allows for the collection of all study data in one location. Study data can be easily shared with authorised users and raw data can be easily downloaded for analysis. |
Title | SAIL Dementia eCohort (SAILDeC) |
Description | DPUK has funded the creation of the SAIL (Secure Anonymised Information Linkage) Databank Dementia eCohort, known as SAILDeC. A team from the University of Edinburgh, led by Dr Tim Wilkinson and Dr Christian Schnier, have developed a research cohort from routine healthcare records found in the SAIL Databank, a research databank containing routine healthcare and adminstrative records for the Welsh populace. The eCohort is derived from 1.2 million individuals who met the inclusion criteria, and of those, ~130,000 dementia cases throughout the data coverage have been identified. This represents the first UK research-ready disease cohort derived solely from routine healthcare records, which can be analysed in its own right or combined with other rich sources of cohort and routine data. It is thought that the technical components of creating the cohort, in terms of coding and initial analysis, could be the lead for future eCohort generation in other disease fields. These eCohorts could then be analysed within their specific area of science, or combined for a rich multi-morbidity database. |
Type Of Material | Database/Collection of data |
Year Produced | 2019 |
Provided To Others? | Yes |
Impact | This is the first disease-specific eCohort of patients to be created from ~20 years of routine healthcare data. It provides a rich dementia-specific resource for episodic progression of patients with initial MCI through to mortality, and every stage in between. The process of creating the cohort can inform the creation of such cohorts from the SAIL source and other routine clinical data sources in many disease areas. |
Title | a github repository |
Description | This pipeline takes a published mouse gene list for astrocytes, converts to human, and creates a file for grch38 with and without the APOE region. |
Type Of Material | Data analysis technique |
Year Produced | 2024 |
Provided To Others? | No |
Impact | This tool will used for a publication which is currently in preparation. |
URL | https://github.com/seafloor/escott-price-lab-pipelines/tree/main |
Title | iPSC resource for researchers |
Description | iPSC resources available are listed on DPUK website where they can download iPSC directory provides the opportunity for researchers to formally request over 100 stem cell lines derived from healthy and diseased individuals |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
Impact | Valuable way for researchers to find out about available resource |
URL | https://www.dementiasplatform.uk/for-researchers/expert-communities-1/stem-cells-network-1/ipsc-reso... |
Description | ADNI multicentre study |
Organisation | Alzheimer's Disease Neuroimaging Initiative |
Country | United States |
Sector | Academic/University |
PI Contribution | NA |
Collaborator Contribution | NA |
Impact | NA |
Start Year | 2010 |
Description | AMYPAD |
Organisation | Amyloid Imaging to Prevent Alzheimer's Disease |
Country | European Union (EU) |
Sector | Public |
PI Contribution | JMS is UCL lead for AMYPAD at UCL - which has interdependencies with DPUK through EPAD |
Collaborator Contribution | Design of protocols |
Impact | Project recently commenced |
Start Year | 2016 |
Description | ARUK's DEMON network and DPUK Reach partnership |
Organisation | Alzheimer's Research UK |
Department | Alzheimers Research UK, Cambridge |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Dr Sarah Bauermeister sits on ARUK's Deep Dementia Phenotyping ('DEMON') steering group. DEMON is a national network for data science and AI in dementia research - connecting together to work on new analytical solutions for dementia research. |
Collaborator Contribution | DPUK Reach is a Data Portal and/or ECR online support user group. It supports DEMON's aims by hosting a forum website which allows researchers to discuss cohorts, analyses, codes, statistical approaches, events and more. |
Impact | DPUK Reach has been launched as a way of DPUK Datathon participants to prepare and carry on for their Data Portal analyses, |
Start Year | 2019 |
Description | ASAP SynTau: Alignment and Standardization of Neuroimaging Methods in Atypical Parkinsonism, specifically Synucleinopathies and Tauopathie |
Organisation | EU Joint Programme - Neurodegenerative Disease Research (JPND) |
Country | European Union (EU) |
Sector | Public |
PI Contribution | This Working Group brings together neuroimaging experts from all over the world to develop a broad, community-based consensus on imaging protocols. These outcomes will help pave the way for the integration of neuroimaging in large and longitudinal multi-centre studies in AP, including therapeutic trials. Meetings, harmonisation of imaging data, workshops, and later data sharing. |
Collaborator Contribution | Meetings, harmonisation of imaging data, workshops, and later data sharing. |
Impact | A project initiation report is submitted to JPND. Data sharing agreements are in progress. |
Start Year | 2016 |
Description | ASO in Familial AD (APP) |
Organisation | Wave Life Sciences |
Country | United States |
Sector | Private |
PI Contribution | Provision of samples including IPSC as well as clinical expertise |
Collaborator Contribution | Provision of ASO's and therapeutic expertise |
Impact | Not yet available |
Start Year | 2018 |
Description | Abeta functional assays |
Organisation | University of Oxford |
Department | Department of Psychiatry |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have worked to develop improved in vitro analysis odf Abeta function |
Collaborator Contribution | Collaborative development of assay |
Impact | Ongoing collaboration |
Start Year | 2015 |
Description | Alan Turing Institute Datathon - a collaboration between ATI, Deep and Frequent Phenotyping and DPUK |
Organisation | Alan Turing Institute |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Data scientists from many different backgrounds combined their expertise to take on dementia in an unusual format for disease research: a three-day datathon. The intensive research event saw teams come together to work on data that is now available in the DPUK Data Portal. The datathon was jointly organised by DPUK, the Deep and Frequent Phenotyping (DFP) study, and the Alan Turing Institute. The DFP pilot study provided the data and the DPUK Data Portal was the means to work with it. Professor Terry Lyons (UOXF Department of Mathematics) is a leading mathematician with innovative contributions to the analysis of multimodal streamed data and methods that have been applied successfully in mental health contexts. He is also a Turing Fellow. With Dr Andrey Kormilitzin (UOXF), he helped to bring the event to fruition. |
Collaborator Contribution | The Alan Turing Institute hosted and organised the event, and, as the national institute for data science in the UK, was an ideal partner to bring big data specialists to the great challenges in dementia research. Working with the Alan Turing Institute helped to emphasise one of DPUK's core areas of focus: dementia is not just a challenge that psychiatrists or cognitive neuroscientists can solve alone. Data scientists have a hugely important role to play now that we have the data and the DPUK technology available. |
Impact | The datathon attracted analysts of all stripes, many of whom had not worked with dementia cohort datasets before. Most of the participants were genuinely excited about the data, datathon and the presentations. We are planning on follow up events, perhaps more focussed on each data type at a time. We're hoping to create a community of experts in these particular data and applications of innovative data science methods for Alzheimer's research. This project brings together several modes of information for people with dementia and will likely play a critical role in understanding how to contrast and compare the different perspectives provided by different types of data. |
Start Year | 2018 |
Description | BRACE |
Organisation | University of Bristol |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | advice and training on genomic data analysis |
Collaborator Contribution | Investigating the genetic overlap between AD and other diseases or traits using polygenic risk scores in Avon Longitudinal Study of Parents and Children (ALSPAC) |
Impact | 1. Application of newly developed methodology (MR-Base), which hallows to do rapid high-throughput analysis of potentially interesting traits and environmental exposures. 2. Test for shared genetic susceptibility between AD and early life lipid levels, glycaemic, anthropometric, behavioral and cognitive traits in ALSPAC children |
Start Year | 2016 |
Description | BioFIND - JPND |
Organisation | EU Joint Programme - Neurodegenerative Disease Research (JPND) |
Country | European Union (EU) |
Sector | Public |
PI Contribution | We led the JPND award on the use of MEG in harmonisation and standarisation for Dementia research, bringing together Pharma and Academic partners from ten sites. |
Collaborator Contribution | Expertise, knowledge sharing, and scoping of future project needs. |
Impact | A project initiation report is submitted. A new data sharing project has begun across six sites. |
Start Year | 2016 |
Description | CLEAR-Huntington's Disease |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Provision of MEG-related methods and analysis advice (postdocs involved: Dr Laura Hughes and Dr Ece Kocagoncu). |
Collaborator Contribution | N/A |
Impact | Cambridge and UCL collaboration only. |
Start Year | 2019 |
Description | CMIC |
Organisation | University College London |
Department | Centre for Medical Image Computing |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Provision of scans and clinical expertise and clinical material |
Collaborator Contribution | Image analysis techniques; processing of data; access to computer clusters PhD students |
Impact | papers ideas for research grants multi-disciplinary - clinicians, computer scientists, physicists |
Description | Cambridge 7T consortium |
Organisation | Medical Research Council (MRC) |
Department | MRC Cognition and Brain Sciences Unit |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Forming the new University-MRC partnership and Cambridge 7T consortium. Full access to new facility for both partners. |
Collaborator Contribution | Staff allocation for physics support and adjunctive technologies for participant interaction. |
Impact | Multidisciplinary - dementia, neurology, psychiatry, development and ageing, cognitive neuroscience and physics. New head of 7T department has been recruited. |
Start Year | 2015 |
Description | Cambridge Centre for Ageing and Neuroscience |
Organisation | University of Cambridge |
Department | Cambridge Neuroscience |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | My research team has received the permission and access to the genetic data of the CamCan cohort with the aim to analyse the genetic data and calculate dementia related PRS for this cohort. |
Collaborator Contribution | The partners have provided us with the data |
Impact | not yet |
Start Year | 2022 |
Description | Cardiovascular drugs and dementia |
Organisation | University of Glasgow |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Advice on statistical data analyses |
Collaborator Contribution | Collaboration with clinicians to assess a variety of medications and validity of the 'dementia' diagnosis |
Impact | Collaboration between clinicians and data analysts |
Start Year | 2024 |
Description | Collaboration with Dr Ece Kocagoncu for NTAD (Dr A Jafarian) |
Organisation | University of Cambridge |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Collaboration on data analysis of test-retest data from NTAD. |
Collaborator Contribution | Availability of NTAD data. |
Impact | Title: Test-reTest reliability of dynamic casual modelling of resting states MEG data of Alzheimer patients. |
Start Year | 2022 |
Description | Collaboration with Dr Natelie E Adams for NTAD (Dr A Jafarian) |
Organisation | University of Cambridge |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Analysis methods for Dynamic causal modelling informed by Positron emission data |
Collaborator Contribution | Data Analysis |
Impact | NTAD Study Results |
Start Year | 2021 |
Description | Collaboration with Dr Nicholas Ashton at the University of Gothenburg |
Organisation | University of Gothenburg |
Country | Sweden |
Sector | Academic/University |
PI Contribution | "Synaptic fluid markers in dementia", sharing expertise in field. |
Collaborator Contribution | "Synaptic fluid markers in dementia", sharing expertise in field. |
Impact | Advancing biomarker discovery projects. |
Start Year | 2022 |
Description | Collaboration with Dr. Gil Rabinovici at the Memory and Aging Center, Department of Neurology, University California San Francisco |
Organisation | University of California, San Francisco |
Country | United States |
Sector | Academic/University |
PI Contribution | Collaboration on project "Tau-PET and domain-specific cognitive decline in Alzheimer's disease", cross fertilization of research expertise. |
Collaborator Contribution | Hosted Post-Doc Dr M. malpetti for 4 month fellowship at UCSF. |
Impact | Reasearch paper: Malpetti M, La Joie R, Rabinovici GD. Tau beats amyloid in predicting brain atrophy in Alzheimer's disease: implications for prognosis and clinical trials. 2022, Journal of Nuclear Medicine - doi: 10.2967/jnumed.121.263694 |
Start Year | 2022 |
Description | Collaboration with Dr. Gil Rabinovici, Dr. Rik Ossenkoppele, Dr. Victoria Pelak, Dr. Keir Yong and ISTAART PIA for Atypical AD |
Organisation | University of San Francisco |
Country | United States |
Sector | Academic/University |
PI Contribution | Collaboration on project "Clinicopathological Correlates in Posterior Cortical Atrophy" |
Collaborator Contribution | Hosted Dr M Malpetti (Post-Doc Rowe Group) for 4 month fellowship at UCSF. |
Impact | Papers in draft & ongoing research activity |
Start Year | 2022 |
Description | Collaboration with Dr. Matthias Brendel at the Ludwig Maximilian University of Munich (Germany) and Prof. Pedro Rosa-Neto at the McGill University (Canada) |
Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
Country | Germany |
Sector | Academic/University |
PI Contribution | TSPO PET in tauopathies project, sharing of expertise |
Collaborator Contribution | TSPO PET in tauopathies project, sharing of expertise |
Impact | Research advancement |
Start Year | 2022 |
Description | Collaboration with Eisai AiM Institute |
Organisation | Eisai Ltd |
Department | Eisai Inc |
Country | United States |
Sector | Private |
PI Contribution | Consultancy on Polygenic risk score for clinical trials |
Collaborator Contribution | We are in the process of negotiations |
Impact | potentially this collaboration will pay for a time of a postdoctoral researcher |
Start Year | 2018 |
Description | Collaboration with European Bioinformatics institute |
Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We plan to provide a software for polygenic risk score calculation and prosess the GWAS summary statistics for all current GWASes available in EBI GWAS catalogue |
Collaborator Contribution | provide data access to the GWAS catalogue |
Impact | This collaboration will provide the GWAS processed data to the research community for quick and efficient calculation of polygenic risk score for any disorder (stored in the EBI GWAS catalogue) |
Start Year | 2019 |
Description | Collaboration with Ludwig Maximillian University |
Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
Department | University Clinic of Munich |
Country | Germany |
Sector | Academic/University |
PI Contribution | Overlap with group research interests and activiity. Collaboration focuses on ageing and dementia. |
Collaborator Contribution | Academic expertise. |
Impact | In progress. |
Start Year | 2022 |
Description | Collaboration with Prof. Giuseppe Baselli, Department of Electronics, Information and Bioengineering |
Organisation | Polytechnic University of Milan |
Country | Italy |
Sector | Academic/University |
PI Contribution | I hosted two students from Prof. Baselli's group (Valentina Bordin and Ilaria Bertani) for their MSc thesis and trained them in neuroimaging analysis methods. |
Collaborator Contribution | The students contributed to the project (DPUK - Discovery Award 2018 - PI: Ludovica Griffanti) by performing data analysis, presenting a conference poster and writing a journal article. |
Impact | The collaboration resulted in a poster presentation at the organisation for human brain mapping (OHBM) conference. Title: "Harmonising measures of white matter hyperintensities across sites and studies: impact of training and manual rating in FSL-BIANCA". The scientific journal article is available as preprint and currently under peer-review. Valentina Bordin has ben awarded with a scholarship to fund a PhD in biomedical engineering. Thanks to the skills learnt as part of this project, she is planning focus on assessing the utility of MRI as a marker for evaluating the efficacy of tele-rehabilitation in dementia. |
Start Year | 2018 |
Description | Collaboration with Professor Francesco Sardanelli, Dept. of Radiology University of Milan, IRCCS Policlinico San Donato |
Organisation | IRCCS Policlinico San Donato |
Country | Italy |
Sector | Hospitals |
PI Contribution | I hosted a PhD student from Prof. Sardanelli's group (Dr. Luca Melazzini) and trained him in neuroimaging analysis methods. |
Collaborator Contribution | The student contributed to the project (DPUK - Discovery Award 2018 - PI: Ludovica Griffanti) by performing data analysis and interpretation, submitting a conference poster and writing a journal article. |
Impact | The collaboration resulted in an abstract accepted as oral presentation at the European Congress of Radiology (ECR) 2020. "Classifying white matter hyperintensities according to intensity and spatial localisation reveals specific association with cognition". The scientific journal article is under review. Dr. Melazzini submitted his PhD thesis (including work part of this collaboration) and will defend in March 2021. |
Start Year | 2019 |
Description | Collaboration with Professor Francesco Sardanelli, Dept. of Radiology University of Milan, IRCCS Policlinico San Donato |
Organisation | University of Milan |
Country | Italy |
Sector | Academic/University |
PI Contribution | I hosted a PhD student from Prof. Sardanelli's group (Dr. Luca Melazzini) and trained him in neuroimaging analysis methods. |
Collaborator Contribution | The student contributed to the project (DPUK - Discovery Award 2018 - PI: Ludovica Griffanti) by performing data analysis and interpretation, submitting a conference poster and writing a journal article. |
Impact | The collaboration resulted in an abstract accepted as oral presentation at the European Congress of Radiology (ECR) 2020. "Classifying white matter hyperintensities according to intensity and spatial localisation reveals specific association with cognition". The scientific journal article is under review. Dr. Melazzini submitted his PhD thesis (including work part of this collaboration) and will defend in March 2021. |
Start Year | 2019 |
Description | Confidentiality & Material Transfer Agreements with Apellies Pharmaceuticals, Inc. |
Organisation | Apellis Pharmaceutical |
Country | United States |
Sector | Private |
PI Contribution | Focussed on the areas of synaptic health and fnction in dementia and neurodegeneration. |
Collaborator Contribution | As per agreement. |
Impact | Partnership ongoing, impacts expected in due course. |
Start Year | 2022 |
Description | Covid19 Neuroscience Group @7T |
Organisation | Imperial College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | New program of research into acute and chronic effects of COVID19 on the brain, including respiratory, cognitive and mental health effects Data collection of inpatients, and those recovering, from severe COVID19, and innovations in brain stem neurochemical imaging |
Collaborator Contribution | Expertise in spectroscopy and respiratory control from the brain Expertise in remote cognitive testing and normative data |
Impact | Pending publications Conference papers accepted, ISMRN, BNA |
Start Year | 2020 |
Description | Covid19 Neuroscience Group @7T |
Organisation | University of Oxford |
Department | Oxford Neuroscience |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | New program of research into acute and chronic effects of COVID19 on the brain, including respiratory, cognitive and mental health effects Data collection of inpatients, and those recovering, from severe COVID19, and innovations in brain stem neurochemical imaging |
Collaborator Contribution | Expertise in spectroscopy and respiratory control from the brain Expertise in remote cognitive testing and normative data |
Impact | Pending publications Conference papers accepted, ISMRN, BNA |
Start Year | 2020 |
Description | DDI and DPUK |
Organisation | Alzheimer's Research UK |
Department | UCL Drug Discovery Institute |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | - JG suggested to introduce the two platforms in turn to gain a better idea of the focuses of each. Given that DPUK funding has been renewed for a further five years from July 2020, it was suggested to discuss 'DPUK2' as opposed to the current scientific programme in place. - The DPUK2 Data Portal and Informatics theme will continue into DPUK2. A manuscript describing the Data Portal has been published today on the European Journal of Epidemiology website. The Data Portal provides secure remote access to unprecedented volume and depths of data, hosting 42 population cohort studies and millions of individuals' anonymised information. - DPUK2 will also been involved in precision recruitment to trials through the Trial Delivery Framework - a structure which will allow highly targeted, richly phenoyped, risk-stratified populations to be consented for re-contact to Experimental Medicine (EM) studies. The Trials Delivery Framework aims to support centres to serve wider recruitment to early phase trials (eg Phase 0 to 1b, rather than later), but does not propose completely reinventing current systems - it will be aligning what is already in place and improving their efficiency. - The EM incubator theme in DPUK2 capitalises on the private public partnership success within DPUK1 - it is a cross-industry pool of companies and academics in a pre-competitive space. The focus of the EM Incubator is largely on human trials, asking questions on how we can best validate targets for humans. - DPUK2 industrial partners are highly supportive of the collaborative environment of the platform, enabling them to achieve understanding early on how companies can best move into drug development and use. - Therefore DPUK2 as a whole has an overall focus on translation and experimental studies. The platform would like to put these services to DDI and gain a better understanding on how DPUK can, for example, support discovery molecules being passed on to other entities. |
Collaborator Contribution | - Please see PowerPoint slide deck '200424 DDA slides for DPUK' for reference - JD described the network of the three DDIs (Oxford, Cambridge, UCL), which overall primarily focus on drug design, synthesis, target ID and validation - screening through to an in vivo Proof of Concept (POC) end point. The institutes sit between academia and industry, with the DDIs often reflecting the interests of the researchers involved. The network aims to take early targets and 'de-risk' them, ahead of passing to industry to develop the drugs further. - The lead molecules isolated by the DDIs are not clinical candidates - it could be up two years of further funding before a reasonable clinical candidate is obtained. However, the DDI network needs to think about translation into humans from the beginning, given that is the target's ultimate aim. - Indeed, although the DDI focuses on producing an in vivo POC endpoint, it is has been clear from the past few years that industrial partners are increasingly looking for the network to provide a blueprint of how these targets can translate into clinic. - The Cambridge DDI has a key focus on proteostasis, with some neuroimmune, neuronal health and vascular research. - The Oxford DDI focuses mostly on neuroimmunity and Alzheimer's Disease, due to the disease's strong genetic component to inform target design. There is also research into organelle dysfunction (mostly in Parkinson's) and some target classes (ligases, kinases etc) - The UCL DDI interests focus on microglia, astrocytes and synaptic health, and takes part in opportunistic research on vascular, mitophagy and b-amyloid questions. A spin-out involving astrocytes (Astronautics) has been successful. There is a strong crossover of research with the Oxford DDI. |
Impact | - Potential opportunities for collaboration between DDI and DPUK include: - Translational biomarkers ? Target engagement ? Proof of mechanism - Experimental medicine for novel mechanisms - Patient stratification (for novel mechanisms) - Human data to support novel target ID & validation |
Start Year | 2020 |
Description | DPUK |
Organisation | Medical Research Council (MRC) |
Country | United Kingdom |
Sector | Public |
PI Contribution | Steering Group member, DPUK work package lead. |
Collaborator Contribution | Creating Dementia Platform UK Data Portal |
Impact | In the process of creating on-line database with dementia cohorts, available in the UK and pipelines for data analyses. Multidisceplinary: genetics, bioinfirmatics, IT. |
Start Year | 2014 |
Description | DPUK Cambridge |
Organisation | University of Cambridge |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Optimisation of high-content imaging protocols with Opera Phenix imager |
Collaborator Contribution | The ARUK Stem Cell Research Centre, Cambridge has standardised the use of the Opera Phenix and Nanostring Sprint instruments for QC in iPSC reprogramming and cproduction of cortical neurons. The Phenix is used for high-throughput imaging of pluripotency markers in patient-derived lines that are generated at the centre. The lab has established a method for routine characterisation of cortical neuron productions using the Nanostring digital gene expression platform. This will facilitate harmonisation of protocols between DPUK centres, and within the STEMBANCC consortium. The imaging platform has been used to develop methods for production of human microglia from iPSCs, and to study cell biology in patient iPSC-derived microglia, focussing on TREM2 mutatiosn. In collaboration with Talisman Therapeutics and AstraZeneca, assays have been established to measure protein uptake in cortical neurons by live imaging. |
Impact | Development of a strong Dementia Stem Cell Network in DPUK |
Start Year | 2016 |
Description | DPUK DSCN |
Organisation | Cardiff University |
Department | School of Biosciences |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Forming DPUK Dementia Stem Cell Network |
Collaborator Contribution | Forming DPUK Dementia Stem Cell Network |
Impact | Collaborations and interactions |
Start Year | 2015 |
Description | DPUK DSCN |
Organisation | University College London |
Department | Medical School |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Forming DPUK Dementia Stem Cell Network |
Collaborator Contribution | Forming DPUK Dementia Stem Cell Network |
Impact | Collaborations and interactions |
Start Year | 2015 |
Description | DPUK DSCN |
Organisation | University of Cambridge |
Department | Gurdon Institute |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Forming DPUK Dementia Stem Cell Network |
Collaborator Contribution | Forming DPUK Dementia Stem Cell Network |
Impact | Collaborations and interactions |
Start Year | 2015 |
Description | DPUK DSCN |
Organisation | University of Edinburgh |
Department | MRC Centre for Regenerative Medicine |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Forming DPUK Dementia Stem Cell Network |
Collaborator Contribution | Forming DPUK Dementia Stem Cell Network |
Impact | Collaborations and interactions |
Start Year | 2015 |
Description | DPUK DSCN |
Organisation | University of Manchester |
Department | Manchester Medical School |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Forming DPUK Dementia Stem Cell Network |
Collaborator Contribution | Forming DPUK Dementia Stem Cell Network |
Impact | Collaborations and interactions |
Start Year | 2015 |
Description | DPUK Data Discovery Tools Categorisation and Coding Programme |
Organisation | University of Oxford |
Department | Department of Psychiatry |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Provide data from our cohort |
Collaborator Contribution | Create Data discovery tool |
Impact | Still ongoing |
Start Year | 2018 |
Description | DPUK Imaging Consortium |
Organisation | MRC Dementias Platform UK |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Sharing of Imaging protocols and data management structures |
Collaborator Contribution | N/A |
Impact | Project recently commenced |
Start Year | 2016 |
Description | DPUK Tau Partnership |
Organisation | Life Molecular Imaging |
Country | Germany |
Sector | Private |
PI Contribution | The partnership involves the use of a novel PET tracer (PI2620) developed by Life Molecular Imaging to carry out Tau PET imaging in existing DPUK cohorts (specifically, the PREVENT AD cohort and the AMYPAD PNHS cohort) |
Collaborator Contribution | LMI (part of the Alliance Medical Group) brings industry expertise in molecular imaging of degenerative brain disease to the Tau-PET study. This study will benefit from a key investigational compound used for PET imaging which is being developed by LMI. |
Impact | Collaboration between industry and DPUK (Neurology, Radiology, Nuclear MedicineEpidemiology, Psychiatry). |
Start Year | 2019 |
Description | DPUK industry partnership |
Organisation | Araclon Biotech |
Country | Spain |
Sector | Private |
PI Contribution | The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia |
Collaborator Contribution | Expertise and technologies |
Impact | Please refer to the following link: http://brain.oxfordjournals.org/content/138/12/3673 |
Start Year | 2014 |
Description | DPUK industry partnership |
Organisation | AstraZeneca |
Department | MedImmune |
Country | United Kingdom |
Sector | Private |
PI Contribution | The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia |
Collaborator Contribution | Expertise and technologies |
Impact | Please refer to the following link: http://brain.oxfordjournals.org/content/138/12/3673 |
Start Year | 2014 |
Description | DPUK industry partnership |
Organisation | GlaxoSmithKline (GSK) |
Department | Neurology and GI Centre of Excellence for Drug Discovery (CEDD) GSK |
Country | United Kingdom |
Sector | Private |
PI Contribution | The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia |
Collaborator Contribution | Expertise and technologies |
Impact | Please refer to the following link: http://brain.oxfordjournals.org/content/138/12/3673 |
Start Year | 2014 |
Description | DPUK industry partnership |
Organisation | Ixico |
Country | United Kingdom |
Sector | Private |
PI Contribution | The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia |
Collaborator Contribution | Expertise and technologies |
Impact | Please refer to the following link: http://brain.oxfordjournals.org/content/138/12/3673 |
Start Year | 2014 |
Description | DPUK industry partnership |
Organisation | Janssen Research & Development |
Country | Global |
Sector | Private |
PI Contribution | The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia |
Collaborator Contribution | Expertise and technologies |
Impact | Please refer to the following link: http://brain.oxfordjournals.org/content/138/12/3673 |
Start Year | 2014 |
Description | DPUK industry partnership |
Organisation | SomaLogic |
Country | United States |
Sector | Private |
PI Contribution | The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia |
Collaborator Contribution | Expertise and technologies |
Impact | Please refer to the following link: http://brain.oxfordjournals.org/content/138/12/3673 |
Start Year | 2014 |
Description | DPUK-2 (2020 - 2025) |
Organisation | University of Oxford |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Calculation of pathway specific PRS, relevant to the Neuroinflammation work package. |
Collaborator Contribution | Access to the DPUK cohorts |
Impact | data access to DPUK cohorts |
Start Year | 2020 |
Description | DSG (Data Study Group) Network |
Organisation | Alan Turing Institute |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | A joint collaboration with the Turing Institue for using the DPUK Data Portal for Workshop - Machine learning - Data Portal infrastructure across DPUK population cohorts. |
Collaborator Contribution | Provision of the data workshop infrastructure - DPUK Data Portal and joint hosting of workshop |
Impact | Newly active March 2019 |
Start Year | 2019 |
Description | DSG (Data Study Group) Network |
Organisation | University of Cambridge |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | A joint collaboration with the Turing Institue for using the DPUK Data Portal for Workshop - Machine learning - Data Portal infrastructure across DPUK population cohorts. |
Collaborator Contribution | Provision of the data workshop infrastructure - DPUK Data Portal and joint hosting of workshop |
Impact | Newly active March 2019 |
Start Year | 2019 |
Description | Dementias Platform Europe - a collaboration between EMIF-AD and DPUK |
Organisation | European Medical Information Framework (EMIF) |
Country | European Union (EU) |
Sector | Charity/Non Profit |
PI Contribution | John Gallacher and consultant Prof Derek Hill (advisor to the DPUK1 Executive Team) met with Prof PJ Visser (PI of EMIF) to investigate the possibility of a merger of the two platforms' data and technology, with the support from industry. |
Collaborator Contribution | Prof Visser hosted the 2-day visit in Amsterdam, providing a tour and in-depth analysis of the runnings and technical features of the EMIF platform. |
Impact | Prof Derek Hill provided a written report to internal DPUK colleagues on the potential strengths and challenges of merging with EMIF. Industry partners have shown interest in supporting the scheme with funding, with further meetings due to happen in February 2020 to move the initiative forward. |
Start Year | 2019 |
Description | Dementias Platform UK Stem Cell Partnership |
Organisation | MRC Dementias Platform UK |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | OPDC will share expertise and stem cell lines as part of DPUK Stem Cell Network |
Collaborator Contribution | Members will share expertise and stem cell lines as part of DPUK Stem Cell Network |
Impact | Ongoing |
Start Year | 2016 |
Description | Dementias Platform UK Stem Cell Partnership |
Organisation | University of Edinburgh |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | OPDC will share expertise and stem cell lines as part of DPUK Stem Cell Network |
Collaborator Contribution | Members will share expertise and stem cell lines as part of DPUK Stem Cell Network |
Impact | Ongoing |
Start Year | 2016 |
Description | Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease |
Organisation | McGill University |
Department | Montreal Neurological Institute and Hospital |
Country | Canada |
Sector | Hospitals |
PI Contribution | Laura Parkkinen and team will analyze CSF samples |
Collaborator Contribution | Dr Brit Mollenhauer (University of Gottingen); Dr Alex Iranzo (University of Barcelona); Dr Bradley Boeve, (NIH); Dr Ronald Postuma (McGill University); Dr Elena Antelmi (University of Bologna) who all provide us with CSF samples from longitudinally followed RBD patients. |
Impact | We have received a 2-year project grant entitled "Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease" from PD UK starting from 1st February 2019 |
Start Year | 2018 |
Description | Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease |
Organisation | National Institutes of Health (NIH) |
Country | United States |
Sector | Public |
PI Contribution | Laura Parkkinen and team will analyze CSF samples |
Collaborator Contribution | Dr Brit Mollenhauer (University of Gottingen); Dr Alex Iranzo (University of Barcelona); Dr Bradley Boeve, (NIH); Dr Ronald Postuma (McGill University); Dr Elena Antelmi (University of Bologna) who all provide us with CSF samples from longitudinally followed RBD patients. |
Impact | We have received a 2-year project grant entitled "Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease" from PD UK starting from 1st February 2019 |
Start Year | 2018 |
Description | Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease |
Organisation | University of Barcelona |
Country | Spain |
Sector | Academic/University |
PI Contribution | Laura Parkkinen and team will analyze CSF samples |
Collaborator Contribution | Dr Brit Mollenhauer (University of Gottingen); Dr Alex Iranzo (University of Barcelona); Dr Bradley Boeve, (NIH); Dr Ronald Postuma (McGill University); Dr Elena Antelmi (University of Bologna) who all provide us with CSF samples from longitudinally followed RBD patients. |
Impact | We have received a 2-year project grant entitled "Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease" from PD UK starting from 1st February 2019 |
Start Year | 2018 |
Description | Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease |
Organisation | University of Bologna |
Department | Department of Neurologial Sciences |
Country | Italy |
Sector | Academic/University |
PI Contribution | Laura Parkkinen and team will analyze CSF samples |
Collaborator Contribution | Dr Brit Mollenhauer (University of Gottingen); Dr Alex Iranzo (University of Barcelona); Dr Bradley Boeve, (NIH); Dr Ronald Postuma (McGill University); Dr Elena Antelmi (University of Bologna) who all provide us with CSF samples from longitudinally followed RBD patients. |
Impact | We have received a 2-year project grant entitled "Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease" from PD UK starting from 1st February 2019 |
Start Year | 2018 |
Description | Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease |
Organisation | University of Göttingen |
Country | Germany |
Sector | Academic/University |
PI Contribution | Laura Parkkinen and team will analyze CSF samples |
Collaborator Contribution | Dr Brit Mollenhauer (University of Gottingen); Dr Alex Iranzo (University of Barcelona); Dr Bradley Boeve, (NIH); Dr Ronald Postuma (McGill University); Dr Elena Antelmi (University of Bologna) who all provide us with CSF samples from longitudinally followed RBD patients. |
Impact | We have received a 2-year project grant entitled "Development of alpha-synuclein seeding assay as an early, progression and stratifying biomarker for Parkinson's disease" from PD UK starting from 1st February 2019 |
Start Year | 2018 |
Description | Dominantly inherited alzheimer's network - multi centre study |
Organisation | Washington University in St Louis |
Department | Dominantly Inherited Alzheimer Network |
Country | United States |
Sector | Charity/Non Profit |
PI Contribution | N/a |
Collaborator Contribution | N/A |
Impact | N/A |
Start Year | 2008 |
Description | Dominantly inherited alzheimer's network - multi centre study |
Organisation | Washington University in St Louis |
Department | Dominantly Inherited Alzheimer Network |
Country | United States |
Sector | Charity/Non Profit |
PI Contribution | N/a |
Collaborator Contribution | N/A |
Impact | N/A |
Start Year | 2008 |
Description | Dr Brent Ryan & Derek Narendra NIH Inherited Movement Disorders Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD |
Organisation | National Institutes of Health (NIH) |
Department | National Institute of Neurological Disorders and Stroke (NINDS) |
Country | United States |
Sector | Public |
PI Contribution | Dr Brent Ryan & Derek Narendra NIH Inherited Movement Disorders Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD. Scope: Collaboration to assess mitophagy in models of PD |
Collaborator Contribution | Dr Brent Ryan & Derek Narendra NIH Inherited Movement Disorders Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD. Scope: Collaboration to assess mitophagy in models of PD Publication: Malpartida AB, Williamson M, Narendra DP, Wade-Martins R, Ryan BJ. Trends Biochem Sci. 2020 Dec 12:S0968-0004(20)30278-4. doi: 10.1016/j.tibs.2020.11.007. Online ahead of print. PMID: 33323315 |
Impact | Publication: Malpartida AB, Williamson M, Narendra DP, Wade-Martins R, Ryan BJ. Trends Biochem Sci. 2020 Dec 12:S0968-0004(20)30278-4. doi: 10.1016/j.tibs.2020.11.007. Online ahead of print. PMID: 33323315 |
Start Year | 2020 |
Description | Dr Brent Ryan & Evandro Fang University of Oslo, Norway Scope: Assessment of mitophagy modulators in iPSC models of PD |
Organisation | University of Oslo |
Country | Norway |
Sector | Academic/University |
PI Contribution | Dr Brent Ryan collaborating with Evandro Fang University of Oslo, Norway Scope: Assessment of mitophagy modulators in iPSC models of PD Output: Aman Y, Ryan B, Torsetnes SB, Knapskog AB, Watne LO, McEwan WA, Fang EF. Int Rev Neurobiol. 2020;155:169-202. doi: 10.1016/bs.irn.2020.02.008. Epub 2020 Aug 11. PMID: 32854854 |
Collaborator Contribution | Dr Brent Ryan collaborating with Evandro Fang University of Oslo, Norway Scope: Assessment of mitophagy modulators in iPSC models of PD Output: Aman Y, Ryan B, Torsetnes SB, Knapskog AB, Watne LO, McEwan WA, Fang EF. Int Rev Neurobiol. 2020;155:169-202. doi: 10.1016/bs.irn.2020.02.008. Epub 2020 Aug 11. PMID: 32854854 |
Impact | Publication: Aman Y, Ryan B, Torsetnes SB, Knapskog AB, Watne LO, McEwan WA, Fang EF. Int Rev Neurobiol. 2020;155:169-202. doi: 10.1016/bs.irn.2020.02.008. Epub 2020 Aug 11. PMID: 32854854 |
Start Year | 2020 |
Description | Dr Brent Ryan collaboration with Dr Maria Letizia Lo Faro NDSS |
Organisation | University of Oxford |
Department | Nuffield Department of Surgical Sciences Oxford |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Collaboration with Dr Maria Letizia Lo Faro (NDSS) to investigate the role of mitophagy in models of organ transplantation initiated in 2022. Grants pending. |
Collaborator Contribution | Collaboration with Dr Maria Letizia Lo Faro (NDSS) to investigate the role of mitophagy in models of organ transplantation initiated in 2022. Grants pending. |
Impact | Collaboration with Dr Maria Letizia Lo Faro (NDSS) to investigate the role of mitophagy in models of organ transplantation initiated in 2022. Grants pending. |
Start Year | 2022 |
Description | Dr Brent Ryan collaboration with Dr Mark Cookson |
Organisation | National Institute on Aging |
Department | Laboratory of Neurogenetics |
Country | United States |
Sector | Public |
PI Contribution | Collaboration with Dr Mark Cookson (National Institute on Aging, USA) initiated in 2022 to share proteomics datasets from patient iPSC-derived cell types including dopaminergic neurons and microglia. Not governed by formal agreements (grants pending). |
Collaborator Contribution | Collaboration with Dr Mark Cookson (National Institute on Aging, USA) initiated in 2022 to share proteomics datasets from patient iPSC-derived cell types including dopaminergic neurons and microglia. Not governed by formal agreements (grants pending). |
Impact | n/a |
Start Year | 2022 |
Description | Dr Brent Ryan collaboration with Dr Morten Meyer (University of Southern Denmark). |
Organisation | University of Southern Denmark |
Country | Denmark |
Sector | Academic/University |
PI Contribution | Collaboration with Dr Morten Meyer (University of Southern Denmark). Investigation of RhoA signalling in Parkinson's- student Sissel Ida Schmidt is visiting for 6 months. Publication Okarmus et al 2021. |
Collaborator Contribution | Investigation of RhoA signalling in Parkinson's- student Sissel Ida Schmidt is visiting for 6 months. Publication Okarmus et al 2021. |
Impact | Justyna Okarmus, Jesper F. Havelund, Matias Ryding, Sissel I. Schmidt, Helle Bogetofte, Rachel Heon-Roberts, Richard Wade-Martins, Sally A. Cowley, Brent J. Ryan, Nils J. Færgeman, Poul Hyttel, Morten Meyer, Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism, Stem Cell Reports, Volume 16, Issue 6, 2021, Pages 1510-1526, ISSN 2213-6711, https://doi.org/10.1016/j.stemcr.2021.04.022. (https://www.sciencedirect.com/science/article/pii/S2213671121002174) Abstract: Summary PARK2 (parkin) mutations cause early-onset Parkinson's disease (PD). Parkin is an ubiquitin E3 ligase that participates in several cellular functions, including mitochondrial homeostasis. However, the specific metabolomic changes caused by parkin depletion remain unknown. Here, we used isogenic human induced pluripotent stem cells (iPSCs) with and without PARK2 knockout (KO) to investigate the effect of parkin loss of function by comparative metabolomics supplemented with ultrastructural and functional analyses. PARK2 KO neurons displayed increased tricarboxylic acid (TCA) cycle activity, perturbed mitochondrial ultrastructure, ATP depletion, and dysregulation of glycolysis and carnitine metabolism. These perturbations were combined with increased oxidative stress and a decreased anti-oxidative response. Key findings for PARK2 KO cells were confirmed using patient-specific iPSC-derived neurons. Overall, our data describe a unique metabolomic profile associated with parkin dysfunction and show that combining metabolomics with an iPSC-derived dopaminergic neuronal model of PD is a valuable approach to obtain novel insight into the disease pathogenesis. Keywords: Parkinson's disease; parkin; induced pluripotent stem cells; metabolomics; mitochondria; oxidative stress |
Start Year | 2021 |
Description | Dr Brent Ryan collaboration with Prof. Martin Rossel Larsen & Dr Helle Bogetofte (University of Southern Denmark) |
Organisation | University of Southern Denmark |
Country | Denmark |
Sector | Academic/University |
PI Contribution | Collaboration with Prof. Martin Rossel Larsen & Dr Helle Bogetofte (University of Southern Denmark) to perform post-translational proteomics on iPSC-derived neurons generated in Oxford. Not governed by formal agreements (grants pending). |
Collaborator Contribution | Continuing collaboration with Prof. Martin Rossel Larsen & Dr Helle Bogetofte (University of Southern Denmark) to perform post-translational proteomics on iPSC-derived neurons generated in Oxford. Not governed by formal agreements (grants pending). |
Impact | n/a |
Start Year | 2021 |
Description | EISAI |
Organisation | Eisai Ltd |
Department | Eisai Europe Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | we provide expertise and data analysis of pathways and gene networks related to neurodegeneration |
Collaborator Contribution | The partner provide expertise the the biological definition of neurodegenerative gene networks |
Impact | NA |
Start Year | 2019 |
Description | EMIF-AD and DPUK |
Organisation | European Medical Information Framework (EMIF) |
Country | European Union (EU) |
Sector | Charity/Non Profit |
PI Contribution | Towards DP Europe: What do we want to achieve? Components and technical aspects COMPONENTS v Catalogue • How to integrate DPUK/EMIF Catalogues? • How to implement direct link to dataset if data are stored on platform? v Subject level data platform with data analysis functions Towards DP Europe: What do we want to achieve? Management, funding & future expansions MANAGEMENT v Interaction cohort owners: UK/Europe/Worldwide v Upload cohort data v Harmonization v Managing data requests v MTA/contracting FUNDING v DP UK v DP Europe (Pharma) FUTURE EXPANSIONS v Human Brain Project Medical Informatic platform v GAAIN • DPUK • DP Europe instance (to be hosted outside UK in Europe) v Platform for harmonized subject-level data on tranSMART v Prepad/Switchbox like access to local database v Common Ontology • Which variables to harmonize? TECHNICAL ASPECTS v Integration v Hosting v Maintenance |
Collaborator Contribution | Towards DP Europe: What do we want to achieve? Components and technical aspects COMPONENTS v Catalogue • How to integrate DPUK/EMIF Catalogues? • How to implement direct link to dataset if data are stored on platform? v Subject level data platform with data analysis functions Towards DP Europe: What do we want to achieve? Management, funding & future expansions MANAGEMENT v Interaction cohort owners: UK/Europe/Worldwide v Upload cohort data v Harmonization v Managing data requests v MTA/contracting FUNDING v DP UK v DP Europe (Pharma) FUTURE EXPANSIONS v Human Brain Project Medical Informatic platform v GAAIN |
Impact | Future plans and discussions surrounding the establishment of DPEU. |
Start Year | 2020 |
Description | ENIGMA MEG working group |
Organisation | University of Southern California |
Country | United States |
Sector | Academic/University |
PI Contribution | Supply of a dementia and healthy participants dataset. |
Collaborator Contribution | TBC |
Impact | A new collaboration in development, initiated late 2020 and the first meeting took place in January 2021. |
Start Year | 2021 |
Description | ETH Zurich - Oxford collaboration for functional imaging in a rodent model of Parkinson's disease |
Organisation | ETH Zurich |
Country | Switzerland |
Sector | Academic/University |
PI Contribution | Richard Wade-Martin's lab has engineered the rodent model of Parkinson's disease (human SCA overexpression). This model has been characterized with histology, voltammetry of dopamine release in cell culture, and behaviourally. In collaboration with the Zurich group, Johannes Klein has performed data analysis on the imaging provided by ETH Zurich. |
Collaborator Contribution | Oxford does not currently have the ability to perform high-quality resting state MRI in small animals. Our collaboration partners at ETH of acquired the imaging data, performed pre-processing with motion correction and ICA data cleaning. Together, we have analysed differences in brain networks between mice overexpressing human alpha-synuclein, and alpha-synuclein knockout siblings. |
Impact | The research is ongoing. The imaging data will be published in the coming year. |
Start Year | 2015 |
Description | Electronic health records |
Organisation | National Institutes of Health (NIH) |
Country | United States |
Sector | Public |
PI Contribution | Discussion of data analyses and results using Electronic Health records in the UK databases |
Collaborator Contribution | Discussion of data analyses and results using Electronic Health records in international databases, replication |
Impact | Two papers have been submitted. |
Start Year | 2023 |
Description | Enhancing autophagy flux in Parkinson's disease |
Organisation | AstraZeneca |
Department | Astra Zeneca |
Country | United States |
Sector | Private |
PI Contribution | OPDC test drug like molecules in cellular models of Parkinson's |
Collaborator Contribution | Astra Zeneca to provide drug-like small molecules. |
Impact | Ongoing |
Start Year | 2016 |
Description | Established collaboration with Ira Milosevic, University of Oxford Wellcome Centre for Human Genetics |
Organisation | University of Oxford |
Department | Wellcome Trust Centre for Human Genetics |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | To study synaptic vesicle recycling and STXBP6 biology in our Parkinson's models. Ira will provide the tools and expertise. |
Collaborator Contribution | The collaboration will be to study synaptic vesicle recycling and STXBP6 biology in our Parkinson's models. Ira will provide tools and expertise |
Impact | The collaboration will be to study synaptic vesicle recycling and STXBP6 biology in our Parkinson's models. Ira will provide tools and expertise |
Start Year | 2021 |
Description | European Alzheimer's disease databank |
Organisation | University of Lille |
Country | France |
Sector | Academic/University |
PI Contribution | Machine learning based data analysis |
Collaborator Contribution | Provided access to the data and HPC facilities |
Impact | Paper in preparation |
Start Year | 2022 |
Description | European Prevention of Alzheimers disease project (EPAD) |
Organisation | University of Edinburgh |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | DPUK is contributing towards the trials infrastructure and recruitment tot he EPAD longitudinal cohort study |
Collaborator Contribution | European colleagues are also contributing towards the trials infrastructure and recruitment tot he EPAD longitudinal cohort study |
Impact | Multi-disciplinary: clinicians, imagers, geneticists, statisticians, epidemiologists. |
Start Year | 2016 |
Description | Evaluation of selected CSF proteins as prognostic markers of dementia in patients with Parkinson's disease |
Organisation | Oxford University Hospitals NHS Foundation Trust |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Provision of samples from our cohort |
Collaborator Contribution | Measuring two serum proteins (haptoglobin and homocysteine), as well as two cerebrospinal fluid proteins (Aß1-42 and phospho-tau). |
Impact | Ongoing research |
Start Year | 2016 |
Description | Free living walking behaviour in a cohort of people with RBD |
Organisation | Newcastle University |
Department | Institute of Neuroscience |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | applying the Axivity Device to RBD and Control participants attending Discovery clinic and providing clinical data |
Collaborator Contribution | Further analysis of data to look for evidence of the onset of motor-symptoms. |
Impact | Ongoing research |
Start Year | 2016 |
Description | GENFI study - multi centre study |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | NA |
Collaborator Contribution | NA |
Impact | NA |
Start Year | 2016 |
Description | GR@CE |
Organisation | Catalan Health Institute (ICS) |
Country | Spain |
Sector | Public |
PI Contribution | we analyse the genome-wide data |
Collaborator Contribution | the collaborators provided the data to us |
Impact | it is a multidisciplinary collaboration, involve clinicians, biologists and bioinformaticians |
Start Year | 2020 |
Description | GW4 fellowship |
Organisation | Cardiff University |
Department | Brain Research Imaging Centre (CUBRIC) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | co-supervisor; advice and training on genomic data analysis |
Collaborator Contribution | A researcher, Judith Harrison |
Impact | To explore disease pathways in Alzheimer's disease using MRI Biomarkers and Polygenic Scores |
Start Year | 2017 |
Description | GWAIS |
Organisation | University of Liege |
Country | Belgium |